02.05.2019

12:00 - 13:00 **Type: Industry Satellite Symposium** **Berlin Hall**
Title: Novartis - Industry Satellite Symposium: Innovation in HR+, HER2– advanced breast cancer and the emerging role of biomarkers
Chair(s): Diana Lüftner, DE

12:00 - 12:05 **Welcome and introduction**
D. Lüftner, Berlin, DE

12:05 - 12:25 **Expanding the evidence base for CDK4/6 inhibitors**
D. Lüftner, Berlin, DE

12:25 - 12:35 **The advancing role of PI3K inhibitors**
P.A. Fasching, Erlangen, DE

12:35 - 12:50 **Considerations for PIK3CA mutations: An interactive discussion**
N. Turner, London, GB

12:50 - 13:00 **Audience question & answer**

13:00 - 13:00 **Closing remarks**
D. Lüftner, Berlin, DE

12:00 - 13:00 **Type: Industry Satellite Symposium** **Vienna Hall**
Title: Eisai - Industry Satellite Symposium: Eisai Scientific exchange symposium: Estrogen receptor positive (ER+) advanced breast cancer – What are the therapeutic approaches of the future?
Chair(s): Pier Franco Conte, IT

12:00 - 12:10 **What is the basis of resistance to current ER+ therapies and what is the magnitude of the clinical problem?**
P.F. Conte, Padova, IT

12:10 - 12:40 **What are the broad strategies for mutation directed therapy? Is there a role for an orally-available Selective ER alpha Covalent Antagonist (SERCA)?**
D. Juric, Boston, MA/US

12:40 - 13:00 **Debate with the delegates led by:**
P.F. Conte, Padova, IT

13:00 - 13:30 **Type: Opening session** **Exhibition area**
Title: Welcome reception

13:30 - 13:45	**Type: Opening session** **Title: Opening and welcome** Chair(s): Sibylle Loibl, DE; Giuseppe Curigliano, IT	**Maritim Hall**
13:30 - 13:30	**Session DOI**	
13:45 - 14:15	**Type: Keynote lecture** **Title: The ESMO Breast Cancer Award** Chair(s): Sibylle Loibl, DE; Giuseppe Curigliano, IT	**Maritim Hall**
13:45 - 13:45	**Session DOI**	
13:45 - 14:15	**Award Lecture**	
14:30 - 16:00	**Type: Educational session** **Title: Translational oncology** Chair(s): Carlos Caldas, GB	**Berlin Hall**
14:30 - 14:30	**Session DOI**	
14:30 - 14:50	**Molecular heterogeneity of breast cancer** C. Caldas, Cambridge, Cambridgeshire/GB	
14:50 - 15:10	**Modelling breast cancer using patient-derived models** S. Aparicio, Vancouver, British Columbia/CA	
15:10 - 15:30	**Modelling breast cancer using GEMMs** M. Bentires-Alj, Basel, CH	
15:30 - 15:50	**Developing targeted breast cancer therapies** L. Friedman, South San Francisco, US	
15:50 - 16:00	**Q&A**	

14:30 - 16:00	**Type: Educational session** **Title: Early breast cancer: HER2 positive** Chair(s): Evandro de Azambuja, BE; Michael Untch, DE	**Maritim Hall**

14:30 - 14:30 **Session DOI**

14:30 - 14:50 **Neoadjuvant therapy in ER+ positive disease**
J. Huober, Ulm, DE

14:50 - 15:10 **Adjuvant therapy**
E. Perez, Jacksonville, US

15:10 - 15:30 **Neoadjuvant therapy in ER-negative disease**
A. Prat, Barcelona, ES

15:30 - 15:50 **Extended adjuvant therapy**
M. Martín, Madrid, ES

15:50 - 16:00 **Q&A**

14:30 - 16:00 **Type: Proffered Paper session** **Vienna Hall**
Title: Proffered Paper session 1
Chair(s): Sibylle Loibl, DE; Giuseppe Curigliano, IT

14:30 - 14:30 **Session DOI**

14:30 - 14:45 **150O - Pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression in patients with HER2-positive metastatic breast cancer (MBC)- The PERNETTA trial (SAKK 22/10), a randomized open label phase II study (SAKK, UNICANCER, BOOG)**

S. Krause[1], K. Ribi[2], P. Weder[3], Q. Li[2], L. Vanlemmens[4], M.-A. Gerard[2], J. Lemonnier[5], B. Thürlimann[3], E. Boven[6], H. Bonnefoi[7]; [1]Ulm, DE, [2]Bern, CH, [3]St. Gallen, CH, [4]Lille, FR, [5]Paris, FR, [6]Amsterdam, NL, [7]Bordeaux, CEDEX/FR

14:45 - 15:00 **151O - Single Agent Activity of U3-1402, a HER3-Targeting Antibody-Drug Conjugate, in HER3-Overexpressing Metastatic Breast Cancer: Updated Results from a Phase 1/2 Trial**

K. Yonemori[1], N. Masuda[2], S. Takahashi[1], T. Kogawa[3], T. Nakayama[2], Y. Yamamoto[4], M. Takahashi[5], T. Toyama[6], T. Saeki[7], H. Iwata[6]; [1]Tokyo, JP, [2]Osaka, JP, [3]Kashiwa, JP, [4]Kumamoto, JP, [5]Sapporo, JP, [6]Nagoya, JP, [7]Saitama, JP

15:00 - 15:15 **Invited discussant abstracts 150O and 151O**

S. Verma, Calgary, Alberta/CA

15:15 - 15:30 **152O - First report of AURORA, the Breast International Group (BIG) molecular screening initiative for metastatic breast cancer (MBC) patients (pts)**

P. Aftimos[1], A.M. Antunes De Melo e Oliveira[2], F. Hilbers[1], D. Venet[1], A. Vingiani[3], E. Nili Gal Yam[4], J. Martinez[1], J. Ndozeng[1], A. Irrthum[1], M. Piccart[1]; [1]Brussels, BE, [2]Barcelona, ES, [3]Milano, IT, [4]Ramat Gan, IL

15:30 - 15:45 **1O - Double PIK3CA mutations in cis enhance PI3Kα oncogene activation and sensitivity to PI3Kα inhibitors in breast cancer**

N. Vasan[1], P. Razavi[1], J. Johnson[1], H. Shao[1], E. Reznik[1], M. Smith[1], R. Sebra[1], L. Cantley[2], M. Scaltriti[3], J. Baselga[3]; [1]New York, US, [2]Boston, MA/US, [3]New York, NY/US

15:45 - 16:00 **Invited discussant abstracts 152O and 1O**

F. André, Villejuif, FR

16:00 - 16:30 **Type: Coffee break** **Exhibition area**
Title: Coffee break

16:30 - 18:00	**Type: Educational session** **Title: Selection of high risk /low risk patients** Chair(s): Christos Sotiriou, BE	**Berlin Hall**

16:30 - 16:30 **Session DOI**

16:30 - 16:50 **Gene profiling for risk assessment: Are they still useful?**
C. Sotiriou, Brussels, BE

16:50 - 17:10 **Circulating tumour markers (CTC- ctDNA- exosomes): Toward the holy grail for risk assessment?**
M. Ignatiadis, Brussels, BE

17:10 - 17:30 **Life style factors: Any influence on the risk?**
P. Goodwin, Toronto, Ontario/CA

17:30 - 17:50 **Is there any biomarker to assess late relapse?**
I. Sestak, London, GB

17:50 - 18:00 **Q&A**

16:30 - 18:00 **Type: Educational session** **Maritim Hall**
Title: Early breast cancer: HER2-/HR positive
Chair(s): Charles Perou, US

16:30 - 16:30 **Session DOI**

16:30 - 16:50 **Neoadjuvant endocrine therapy, when and why?**
C. Ma, St. Louis, US

16:50 - 17:10 **Genomics of intrinsic endocrine resistance, new insights and therapeutic hypotheses**
C. Perou, Chapel Hill, NC/US

17:10 - 17:30 **Late relapse and duration of therapy, where are we?**
M. Dowsett, London, GB

17:30 - 17:50 **Ovarian suppression, whom, which agents, how long, and at what cost?**
O. Pagani, Bellinzona, CH

17:50 - 18:00 **Q&A**

16:30 - 17:30 **Type: Mini oral session** **Vienna Hall**
Title: Mini oral session 1
Chair(s): Veronique Dieras, FR; Evandro de Azambuja, BE

16:30 - 16:30 **Session DOI**

16:30 - 16:35 **LBA3 - A pragmatic, randomised, multicentre trial comparing 4-weekly vs. 12-weekly administration of bone-targeted agents (denosumab, zoledronate or pamidronate) in patients with bone metastases.**
M. Clemons[1], C. Stober[1], M. Mates[2], A.A. Joy[3], A. Robinson[2], J. Hilton[1], P. Blanchette[4], O. Aseyev[1], G. Pond[1], D. Fergusson[1]; [1]Ottawa, CA, [2]Kingston, ON/CA, [3]Edmonton, Alberta/CA, [4]London, CA

16:35 - 16:40 **Q&A**

16:40 - 16:45 **6O - Utility of early circulating tumour DNA dynamics as a surrogate for progression free survival in the BEECH phase I/II trial in metastatic breast cancer**

S. Hrebien[1], V. Citi[2], I. Garcia-Murillas[1], R. Cutts[1], I. Kozarewa[3], J. Ratnayake[3], E. de Bruin[3], G. Schiavon[3], A.M. Antunes De Melo e Oliveira[4], N. Turner[1]; [1]London, GB, [2]Pisa, IT, [3]Cambridge, GB, [4]Barcelona, ES

16:45 - 16:50 **Q&A**

16:50 - 16:55 **7O - PAM50MET: a prognostic model based on PAM50 and clinical variables in metastatic hormone receptor (HR)-positive/HER2 negative breast cancer**

A. Prat[1], Y.-H. Tsai[2], T. Pascual[1], L. Paré[1], M. Vidal[1], B. Adamo[1], J. Brase[3], S. Johnston[4], E. Ciruelos[5], J. Parker[2]; [1]Barcelona, ES, [2]Chapell Hill, US, [3]Basel, CH, [4]London, GB, [5]Madrid, ES

16:55 - 17:00 **Q&A**

17:00 - 17:05 **10O - Comparison of Patient Populations Identified by Different PD-L1 Assays in in Triple-Negative Breast Cancer (TNBC)**

M. Scott[1], P. Scorer[1], C. Barker[2], H. Al-Masri[3]; [1]Cambridge, GB, [2]Little Chesterford, GB, [3]Chicago, US

17:05 - 17:10 **Q&A**

17:10 - 17:15 **153O - Response Rate by Geographic Region in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2–Negative Advanced Breast Cancer From the SOLAR-1 Trial**

S. Loibl[1], P.F. Conte[2], M. Campone[3], I. Mayer[4], Y.-S. Lu[5], N. Denduluri[6], C. Wilke[7], A. Ridolfi[8], F. André[9]; [1]Neu-Isenburg, DE, [2]Padova, IT, [3]Saint-Herblain, CEDEX/FR, [4]Nashville, US, [5]Taipei, TW, [6]Arlington, US, [7]Basel, CH, [8]Cambridge, US, [9]Villejuif, FR

17:15 - 17:20 **Q&A**

17:20 - 17:25 **154O - Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the Phase 3 EMBRACA Trial**

P.A. Fasching[1], R. Quek[2], H. Bhattacharyya[3], S. Hurvitz[4], H. Rugo[5], J. Ettl[6]; [1]Erlangen, DE, [2]San Francisco, US, [3]New York, US, [4]Santa Monica, CA/US, [5]San Francisco, CA/US, [6]Munich, DE

17:25 - 17:30 **Q&A**

18:15 - 19:00	**Type: Young Oncologist session** **Title: Vesalius Talk: the importance of mentorship for YO** Chair(s): Matteo Lambertini, IT	**London Hall**

18:15 - 18:15 **Session DOI**

18:15 - 18:20 **Introduction**

M. Lambertini, Genova, IT

18:20 - 19:00 **Panel discussion**

G. Curigliano[1], S. Loibl[2]; [1]Milan, IT, [2]Neu-Isenburg, DE

18:30 - 19:30	**Type: Industry Satellite Symposium** **Title: Medscape - Industry Satellite Symposium: New views on HER2-positive breast cancer: Low HER2, HER3 and resistance**	**Berlin Hall**

18:30 - 18:40 **Welcome and introduction**

G. Curigliano, Milan, IT

18:40 - 18:50 **Taking the Molecular View: Are Grey Areas Less Grey?**

S. Verma, Calgary, Alberta/CA

18:50 - 19:00 **Taking the Clinical View: Who Is the Low HER2+ Patient?**

F. André, Villejuif, FR

19:00 - 19:10 **Taking the Clinical View: Who Is the HER2-Resistant Patient?**

G. Curigliano, Milan, IT

19:10 - 19:20 **Taking the Future View**

E. Hamilton, Nashville, US

19:20 - 19:30 **Program Conclusion Panel and Audience Question and Answer Session**

G. Curigliano, Milan, IT

18:30 - 19:30 **Type: Industry Satellite Symposium** **Vienna Hall**
Title: AstraZeneca - Industry Satellite Symposium: Hitting breast cancer where it hurts
Chair(s): Christian Jackisch, DE

18:30 - 18:35 **Welcome and introductions**
C. Jackisch, Offenbach Am Main, DE

18:35 - 18:55 **Defining the target: The biology of BRCAm disease**
T.-W. Park-Simon, Hannover, DE

18:55 - 19:10 **Picking the right tool: Innovations in breast cancer treatment**
A. Tutt, London, GB

19:10 - 19:25 **Assembling the team: A co-ordinated multidisciplinary approach**
C. Jackisch[1], A. Tutt[2], C. Singer[3], T.-W. Park-Simon[4]; [1]Offenbach Am Main, DE, [2]London, GB, [3]Vienna, AT, [4]Hannover, DE

19:25 - 19:30 **Breaking through breast cancer: Concluding remarks**
C. Jackisch, Offenbach Am Main, DE

03.05.2019

07:45 - 08:30 **Type: Special session** **Berlin Hall**
Title: In collaboration with SIOG: Older patients and breast cancer
Chair(s): Etienne Brain, FR; Sibylle Loibl, DE

07:45 - 07:45 **Session DOI**

07:45 - 07:47 **Introduction**
S. Loibl, Neu-Isenburg, DE

07:47 - 08:00 **INNOVATION: Breast cancer in the elderly is NOT a benign disease**
J. Reis-Filho, New York, NY/US

08:00 - 08:13 **INNOVATION: Do not OVERtreat or UNDERtreat breast cancer in the elderly**
H. Wildiers, Leuven, BE

08:13 - 08:26 **CARE: Supportive measures for Quality of Life and Improved Results**
M. Aapro, Genolier, CH

08:26 - 08:30 **Take home message**
E. Brain, St. Cloud, FR

07:45 - 08:30	**Type: Special session** **Title: Lobular breast cancer: update on everything we know and still don't know** Chair(s): Patrick Derksen, NL	**Riga Hall**

07:45 - 07:45 **Session DOI**

07:45 - 07:50 **Introduction**

P. Derksen, Utrecht, NL

07:50 - 08:05 **Clinical and pathological characteristics of lobular breast cancer: Challenges and opportunities**

A. Vincent-Salomon, Paris, FR

08:05 - 08:10 **Q&A**

08:10 - 08:25 **Molecular features of lobular breast cancer: opportunities for individualizing therapy**

C. Desmedt, Leuven, BE

08:25 - 08:30 **Q&A**

08:30 - 09:30	**Type: Controversy session** **Title: Platinum agents in the neoadjuvant setting for TNBC** Chair(s): Javier Cortes Castan, ES	**Vienna Hall**

08:30 - 08:30 **Session DOI**

08:30 - 08:40 **Introduction and first vote**

08:40 - 09:00 **Pro**

S. Verma, Calgary, Alberta/CA

09:00 - 09:20 **Contra**

S. Delaloge, Villejuif, FR

09:20 - 09:30 **Second vote and conclusions**

08:45 - 10:15 **Type: Proffered Paper session** **Berlin Hall**
Title: Proffered Paper session 2
Chair(s): Giuseppe Curigliano, IT

08:45 - 08:45 **Session DOI**

08:45 - 09:00 **2O - Prognostic value of EndoPredict for invasive lobular carcinomas in the combined ABCSG-6/8 and TransATAC trials**

I. Sestak[1], M. Filipits[2], R. Buus[1], M. Rudas[2], M. Knauer[3], R. Kronenwett[4], J. Cuzick[1], M. Gnant[2], M. Dowsett[1], P. Dubsky[5]; [1]London, GB, [2]Vienna, AT, [3]St. Gallen, CH, [4]Köln, DE, [5]Luzern, CH

09:00 - 09:15 **123O - Variation in radiotherapy after breast conserving surgery in patients aged 75 years or older between hospitals is not reflected in the locoregional recurrence risk**

A. de Boer[1], N. De Glas[1], P. Marang-van de Mheen[1], O. Dekkers[1], S. Siesling[2], J. Portielje[1], E. Bastiaannet[1], G.-J. Liefers[1]; [1]Leiden, NL, [2]Utrecht, NL

09:15 - 09:30 **Invited discussant: 2O and 123O**

I. Kunkler, Edinburgh, Midlothian/GB

09:30 - 09:45 **3O - Comprehensive evaluation of methodology to assess abundance of immune infiltrates in breast cancer**

I. Nederlof[1], D. de Bortoli[2], Y. Bareche[3], G. Hooijer[1], C. Sotiriou[3], M. van de Vijver[1], H. Horlings[1], R. Salgado[4], E. Biganzoli[2], C. Desmedt[5]; [1]Amsterdam, NL, [2]Milan, IT, [3]Brussels, BE, [4]Antwerp, BE, [5]Leuven, BE

09:45 - 10:00 **4O - Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (pembro)+chemotherapy (CT) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): phase Ib KEYNOTE-173 trial**

S. Loi[1], P. Schmid[2], G. Aktan[3], V. Karantza[3], R. Salgado[3]; [1]Melbourne, VIC/AU, [2]London, GB, [3]Kenilworth, US

10:00 - 10:15 **Invited discussant: 3O and 4O**

C. Denkert, Marburg, DE

08:45 - 10:15 **Type: Educational session** **Maritim Hall**
Title: Early breast cancer: TNBC
Chair(s): Miguel Martín, ES

08:45 - 08:45 **Session DOI**

08:45 - 09:05 **TNBC: Are all tumors equal? The pathologists view**
C. Denkert, Marburg, DE

09:05 - 09:25 **Prognosis factors of early TNBC patients**
S. Loi, Melbourne, VIC/AU

09:25 - 09:45 **Neo/Adjuvant therapy of early TNBC**
S. Loibl, Neu-Isenburg, DE

09:45 - 10:05 **Management of early TNBC in BRCA 1-2 mutation carriers**
A. Tutt, London, GB

10:05 - 10:15 **Q&A**

08:45 - 10:15	**Type: Special session** **Title: In collaboration with Europa Donna: Patient Advocates' role in research** Chair(s): Ellen Verschuur-van der Voort, NL; Elizabeth Bergsten Nordström, SE	**Riga Hall**

08:45 - 08:45 **Session DOI**

08:45 - 09:05 **PRECISION (PREvent ductal Carcinoma In Situ Invasive Overtreatment Now)**
J. Wesseling, Amsterdam, NL

09:05 - 09:25 **Patient advocate role PRECISION**
E. Verschuur-van der Voort, Bloemendaal, NL

09:25 - 09:35 **Overview of Europa Donna's role in current research**
K. Benn, Milan, IT

09:35 - 09:45 **Patient advocate role in EBCTCG and IBCSG**
E. Bergsten Nordström, Norrköping, SE

09:45 - 09:55 **Patient role in POSITIVE**
T. Spanic, Ljubljana, SI

09:55 - 10:15 **Discussion**

09:45 - 10:15	**Type: Spotlight** **Title: Spotlight on prevention and epidemiology** Chair(s): Fatima Cardoso, PT	**Vienna Hall**

09:45 - 09:45 **Session DOI**

09:45 - 10:05 **Spotlight on prevention and epidemiology**
S. Paluch-Shimon, Jerusalem, IL

10:05 - 10:15 **Discussion**

10:15 - 10:45	**Type: Coffee break** **Title: Coffee break**	**Exhibition area**

10:45 - 12:15 **Type: Educational session** **Berlin Hall**
Title: Personalised medicine
Chair(s): Fabrice André, FR

10:45 - 10:45 **Session DOI**

10:45 - 11:05 **What did we learn from the sequencing of metastatic breast cancers?**
F. André, Villejuif, FR

11:05 - 11:25 **Use of multigene panels for metastatic breast cancers**
F. Marmé, Heidelberg, DE

11:25 - 11:45 **Rare genomic entities in metastatic breast cancers**
C. Massard, Villejuif, CEDEX/FR

11:45 - 12:05 **Trial methodology in precision medicine**
S. Michiels, Villejuif, FR

12:05 - 12:15 **Q&A**

10:45 - 12:15	**Type: Educational session** **Title: Immune oncology** Chair(s): Sherene Loi, AU	**Maritim Hall**

10:45 - 10:45 **Session DOI**

10:45 - 11:05 **Update of current clinical data of checkpoint inhibition in breast cancer**

G. Bianchini, Milano, IT

11:05 - 11:25 **Markers of response and resistance to PD-1; PD-L1 inhibition in solid tumour types - lessons for breast cancer**

11:25 - 11:45 **Immunogramme of breast cancer. Identify predictive biomarkers responsible for immune check points inhibitors**

S. Adams, New York, US

11:45 - 12:05 **Monitoring the immune system- new and old technologies and their clinical implications**

R. Salgado, Wilrijk, BE

12:05 - 12:15 **Q&A**

10:45 - 12:15 **Type: Educational session** **Vienna Hall**
Title: Metastatic breast cancer: HER2 positive
Chair(s): Javier Cortes Castan, ES

10:45 - 10:45 **Session DOI**

10:45 - 11:05 **Understanding antiHER2 mechanisms of resistance**
J. Albanell Mestres, Barcelona, ES

11:05 - 11:25 **Moving into the future understanding the present**
A. Awada, Brussels, BE

11:25 - 11:45 **How to treat brain metastases?**
R. Bartsch, Vienna, AT

11:45 - 12:05 **The role of immunotherapy in HER2+ metastatic breast cancer**
E. de Azambuja, Brussels, BE

12:05 - 12:15 **Q&A**

10:45 - 12:15	**Type: Special session** **Title: In collaboration with ESO: Breast cancer in young women: From guidelines to clinical practice** Chair(s): Olivia Pagani, CH; Fatima Cardoso, PT	**Riga Hall**

10:45 - 10:45 **Session DOI**

10:45 - 11:05 **The biology of breast cancer in young women: What is different**

A. Partridge, Boston, US

11:05 - 11:25 **ESO-ESMO BCY Guidelines: Optimal management of young women with breast cancer**

O. Pagani, Bellinzona, CH

11:25 - 11:45 **Fertility preservation and pregnancy after the disease**

F. Peccatori, Milan, IT

11:45 - 12:00 **Survivorship issues**

S. Paluch-Shimon, Jerusalem, IL

12:00 - 12:15 **Research priorities**

F. Cardoso, Lisbon, PT

12:15 - 13:00	**Type: Poster display session** **Title: Poster lunch**	**Exhibition area**

12:15 - 12:15 **Biomarkers and translational research and precision medicine**

12:15 - 12:15 **11P - mammographic density change and risk of breast cancer**

S. Azam, M. Eriksson, A. Sjölander, R. Hellgren, M. Gabrielson, K. Czene, P. Hall; Stockholm, SE

12:15 - 12:15 **12P - Ductal carcinoma in situ of the breast: Immune cell composition according to subtype**

M.C. Agahozo[1], M. Van Bockstal[2], F. Groenendijk[1], T. van den Bosch[1], P. Westenend[3], C. van Deurzen[1]; [1]Rotterdam, NL, [2]Woluwe-Saint-lambert, BE, [3]No City Provided, NA

12:15 - 12:15 **13P - Dynamic Monitoring of ctDNA Reveals that Acquired NF2 Mutations Confer Resistance to HER2 Targeted Therapy in HER2-mutant Breast Cancer**

X. Li, J. Ma, B. Pan, Z. Zhao, M. Li; Dalian, CN

12:15 - 12:15 **14P - Outcomes of women at high familial risk for breast cancer in Australia: an 8-year single-centre experience**

J. Lammert[1], A. Skandarajah[2], K. Shackleton[2], P. Calder[2], S. Thomas[2], G. Lindeman[2], G.B. Mann[2]; [1]Munich, DE, [2]Melbourne, AU

12:15 - 12:15

15P - Influence of PIK3CA mutations on breast cancer proliferation, lymphocyte infiltration and clinical outcome: pooled analysis of 484 patients from three prospective multicentre GBG trials

P. Jank[1], S. Loibl[2], P.A. Fasching[3], T. Karn[4], F. Marmé[5], V. Mueller[6], C. Schem[6], E. Stickeler[7], B. Lederer[2], C. Denkert[1]; [1]Marburg, DE, [2]Neu-Isenburg, DE, [3]Erlangen, DE, [4]Frankfurt Am Main, DE, [5]Heidelberg, DE, [6]Hamburg, DE, [7]Aachen, DE

12:15 - 12:15

16P - Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer

X. Guan[1], Y. Niu[2], B. Liu[1], C. Li[1], L. Li[1], Z. Yi[1], X. Sun[1], H. Chen[1], F. Ma[1], S. Lu[2]; [1]Beijing, CN, [2]Shanghai, CN

12:15 - 12:15

17P - Are single hormone receptor-positive phenotypes biologically and clinically distinct breast cancer? A population-based study

Y. Li, Y. Wu, D. Yang, H. Li, G. Ren; Chongqing, CN

12:15 - 12:15

18P - Secondary mechanisms of anti-HER2 resistance in breast cancer: NF1 as an actionable target

B. Duso[1], C. Poletti[2], G. Curigliano[2], P. Pelicci[2], L. Mazzarella[2]; [1]Milan, PA/IT, [2]Milan, IT

12:15 - 12:15

19P - The clinical impact of substituting multigene assays: Comparative clinical analysis of PAM50-ROR versus 21-gene assay

C. Markopoulos[1], L. Hochheiser[2], J. Hornberger[3], E. Hytopoulos[3], M. Stoppler[3], M. Gitlin[4]; [1]Athens, GR, [2]Burlington, US, [3]Redwood City, US, [4]Los Angeles, US

12:15 - 12:15

20P - ERBB2 mRNA as predictor of response to anti-HER2 antibody-drug conjugates (ADC) in breast cancer (BC)

G. Griguolo[1], F. Brasó-Maristany[2], T. Pascual[2], N. Chic[2], M. Vidal[2], B. Adamo[2], T. Giarratano[3], M.V. Dieci[3], V. Guarneri[3], A. Prat[2]; [1]Bellinzona, CH, [2]Barcelona, ES, [3]Padova, IT

12:15 - 12:15

21P - Characteristics of circulating tumor DNA (ctDNA) in patients with ER-positive (ER+), HER2-negative (HER2-) metastatic breast cancer (MBC) on different lines of endocrine treatment

M. Bos[1], D. Kruger[2], M. Jansen[1], J. Martens[1], E. Boven[2], S. Sleijfer[1]; [1]Rotterdam, NL, [2]Amsterdam, NL

12:15 - 12:15

22P - ESR1 mutations are similarly prevalent in newly metastatic and loco-regional recurrence of endocrine-treated breast cancer patients and carry worse prognosis

E. Nili Gal Yam, A. Zundelevich, M. Dadiani, A. Itay, T. Sela, M. Gadot, S. Kahana, A. Pavlovsky, I. Barshack, B. Kaufman; Ramat Gan, IL

12:15 - 12:15 **23P - Design of a protein signature predicting response to neo-adjuvant treatment with chemotherapy combined with bevacizumab in breast cancer patients**

M. Haugen[1], O.C. Lingjærde[1], Ø. Garred[1], I. Hedenfalk[2], N. Loman[2], G. Mills[3], A.-L. Borresen-Dale[1], B. Naume[1], G. Mælandsmo[1], O. Engebråten[1]; [1]Oslo, NO, [2]Lund, SE, [3]Houston, TX/US

12:15 - 12:15 **24P - A nomogram integrating reverse phase protein array based proteomic signature and clinical variables improves prognostic prediction in non-metastatic breast cancer after surgery**

Y. Junping[1], Q. Channan[2]; [1]Zhengzhou, CN, [2]Guangzhou, CN

12:15 - 12:15 **25P - Expression of ER, PR, HER2 and Ki67 in the neoadjuvant GeparX trial: Comparison of central immunohistochemistry with an automated cartridge-based system for mRNA assessment (on behalf of the GBG neoadjuvant and translational Subboard)**

C. Denkert[1], P. Jank[1], T. Link[2]; [1]Marburg, DE, [2]Dresden, DE

12:15 - 12:15 **26P - Utilization and Performance of the Prosigna® Breast Cancer Prognostic Gene Signature Assay at the Medical University of Vienna**

K. Tendl[1], L. Monschein[1], R. Exner[2], F. Fitzal[2], E. Bergen[2], M. Seifert[2], C. Singer[2], M. Rudas[2], L. Müllauer[1], Z. Bago-Horvath[2]; [1]Wien, AT, [2]Vienna, AT

12:15 - 12:15 **27P - Biological features of estrogen receptor-positive breast cancer with elevated RANK (TNFRSF11A) expression**

S. Casimiro[1], I. Gomes[2], B. Almeida[2], P. Alves[2], P. Félix[2], G. Vilhais[2], A. Mansinho[1], M.R. Dionísio[2], N. Barbosa-Morais[2], L. Costa[2]; [1]Lisbon, PT, [2]Lisboa, PT

12:15 - 12:15 **28P - Impact of the 21-gene assay on treatment decisions in high-risk patients with ER-positive HER2-negative early breast cancer: results of the KARMA Dx study**

A. Llombart[1], R. Andrés[2], A. Anton Torres[2], N. Martinez[3], C. Rodriguez[4], P. Sánchez-Rovira[5], B. Rojas[6], M. Ruiz Borrego[7], B. Bermejo[3], E. Martinez de Dueñas[8]; [1]Lleida, ES, [2]Zaragoza, ES, [3]Madrid, ES, [4]Salamanca, ES, [5]Jaen, ES, [6]Barcelona, ES, [7]Sevilla, ES, [8]Castellón, ES

12:15 - 12:15 **29P - Heterozygous mutation in Fanconi Anemia genes associated with hereditary breast cancer**

M. Gordiev[1], O. Brovkina[2], L. Shigapova[1], E. Shagimardanova[1], R. Enikeev[1], A. Nikitin[2], V. Petkau[3], A. Aksarin[4], E. Ovchinnikova[5], D. Sakaeva[6]; [1]Kazan, RU, [2]Moscow, RU, [3]Ekaterinburg, RU, [4]Surgut, RU, [5]Nizhny Novgorod, RU, [6]Ufa, Russia/RU

12:15 - 12:15 **30P - Update on the phase 2 SUMMIT trial: neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer**

L. Smyth[1], C. Saura[2], S. Piha-Paul[3], J. Lu[4], I. Mayer[5], A. Brufksy[6], I. Spanggaard[7], M. Arnedos[8], R. Cutler[9], D. Hyman[10]; [1]Dublin, IE, [2]Barcelona, ES, [3]Houston, US, [4]Los Angeles, US, [5]Nashville, US, [6]Pittsburgh, US, [7]Copenhagen, DK, [8]Villejuif, FR, [9]South San Francisco, US, [10]New York, US

12:15 - 12:15

31P - The spatial relations among immune cells are prognostic in inflammatory breast cancer.

C. Van Berckelaer[1], C. Colpaert[2], C. Rypens[3], K. Marien[3], M. Kockx[3], Y. Waumans[3], P. Vermeulen[2], L. Dirix[2], S. Van Laere[3], P. Van Dam[3]; [1]Edegem, BE, [2]Wilrijk, BE, [3]Antwerp, BE

12:15 - 12:15

32P - MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro

L. Svartdal[1], M. Aure[1], S.-K. Leivonen[2], M. Haugen[1], V. Hongisto[3], V. Kristensen[4], G. Mælandsmo[1], K. Sahlberg[5]; [1]Oslo, NO, [2]Helsinki, FI, [3]Turku, FI, [4]Lorenskog, NO, [5]Drammen, NO

12:15 - 12:15

33P - Germline PALB2 heterozygous mutations in breast cancers: haploinsufficiency paradigm

Q. Ouyang[1], Z.-Y. Hu[1], L. Liu[1], J. Gao[1], H. Wu[1], J. Lu[1], N. Xie[1], C. Tian[1], Z. Liu[2], Y. Xu[2]; [1]Changsha, CN, [2]Beijing, CN

12:15 - 12:15

34P - Comparison of HER2, estrogen and progesterone receptor expression profiles of primary tumor and synchronous axillary lymph node metastases in 159 breast cancer patients - indicating tumoral heterogeneity.

L. Weydandt, L.-C. Horn, B. Aktas; Leipzig, DE

12:15 - 12:15

35P - Downregulation of immune checkpoints by doxorubicin and carboplatin-containing neoadjuvant regimens in breast cancer; a new insight into the mechanism of induction of antitumor immunity

S. Sadighi, R. Sharifian, M. Kazemimanesh, A. Muhammadnejad, S. Amanpour, S. Muhammadnejad; Tehran, IR

12:15 - 12:15

36P - Endocrine implications in male breast cancer in Bulgaria

A. Konsoulova-Kirova[1], K. Kalchev[1], A. Yordanov[2], S. El Shemeri[1], S. Strashilov[2], S. Maslyankov[3], K. Angelov[3], D. Kostova-Lefterova[2], Y. Marincheva[4], M. Vasileva[3]; [1]Varna, BG, [2]Pleven, BG, [3]Sofia, BG, [4]Burgas, BG

12:15 - 12:15

37P - RNA signatures from tumor-educated platelets (TEP) enable detection of early-stage breast cancer

M. Liefaard[1], E. Lips[1], M. Best[1], N. Sol[1], S. In 'T Veld[1], M. Rookus[1], G. Sonke[1], B.A. Tannous[2], J. Wesseling[1], T. Würdinger[1]; [1]Amsterdam, NL, [2]Boston, US

12:15 - 12:15

38P - Defining the physiological miRNA landscape in nipple aspirate fluid

S. Patuleia, C. Moelans, C. van Gils, P. van Diest, E. van der Wall; Utrecht, NL

12:15 - 12:15 **39P - (Withdrawn)**

12:15 - 12:15 **40P - WNT, Hedgehog and NOTCH signaling pathways in triple negative breast cancer with high and low content of cancer stem cells**

A. Brilliant, Y. Brilliant, S. Sazonov; Ekaterinburg, RU

12:15 - 12:15 **41P - Prognostic significance of BCL-2 expression in triple negative breast cancer (TNBC)**

V. Srinivasalu[1], A. Susan[2], W. Jose[3], A. Philip[4], S. N V[2], A. Nambiar[2], K. Pavithran[3]; [1]Bangalore, IN, [2]Kochi, IN, [3]Kochi, Kerala/IN, [4]Cochin, Tamil Nadu/IN

12:15 - 12:15 **42P - Painting the global picture of HER2-testing for breast cancer. The ONCOLLEGE-001 survey study**

S. Altuna[1], C. Lengyel[2], D. Trapani[3], E. Elfaham[4], S. Hussain[5], A. Petrillo[6], K. El Bairi[7], S. Mazher[8], B. Habeeb[9], S.Z. Khan[10]; [1]Caracas, VE, [2]Budapest, HU, [3]Milan, IT, [4]Alexandria, EG, [5]Riyadh, SA, [6]Napoli, IT, [7]Oujda, MA, [8]Little Rock, US, [9]Erbil, IQ, [10]Peshawar, PK

12:15 - 12:15 **43P - CIP2A as a novel target to combat basal like breast cancer**

S. Nagelli[1], A. Laine[2], T. Suomi[1], L. Elo[1], J. Westermarck[1]; [1]Turku, FI, [2]Amsterdam, NL

12:15 - 12:15 **44P - Prognostic value of Ki-67 in patients with triple-negative breast cancer receiving neo-adjuvant or adjuvant chemotherapy: A systematic review and meta-analysis**

Q. Zhou, W. Li; Chengdu, CN

12:15 - 12:15 **45P - 3D association of ER, PR and Her2 to aid sub-grouping of breast cancer patients**

J. Zhang[1], J. Lv[2], G. Yu[2], L. Li[3], Y. Zhang[2], F. Tang[2]; [1]Research Triangle Park, US, [2]Yantai, CN, [3]Xintai, CN

12:15 - 12:15 **46P - BRCA mutations among Triple Negative Breast Cancer without family history of breast and ovarian cancer: the Modena Family Cancer Clinic experience.**

E. Molinaro, M. Venturelli, A. Toss, C. Piombino, E. Barbieri, L. Marcheselli, I. Marchi, E. Tagliafico, S. Cascinu, L. Cortesi; Modena, IT

12:15 - 12:15 **47P - Palbociclib-induced senescence upregulates the expression of IL-8 and may enhance the response to immunotherapy**

A. Martinez Bueno[1], J. Bertran Aramillo[1], J.J. Garcia Mosquera[2], A. Gimenez Capitan[1], J. Codony-Servat[1], A. Aguilar[1], S. Garcia Román[1], C. Mayo de las Casas[1], S. Viteri[1], M.A. Molina[1]; [1]Barcelona, ES, [2]Badalona, Barcelona/ES

12:15 - 12:15 **48P - Hereditary Breast and Ovarian Cancer Syndrome– Descriptive Analysis of a Familial Cancer Clinic**

S. Amaral[1], T. Cunha Pereira[2], A.R. Monteiro[2], A.R. Garcia[2], L. Pinto[2], V. Gonçalves[2], M. Mariano[2], S. Broco[2], T. Carvalho[2], G. Sousa[2]; [1]Porto, PT, [2]Coimbra, PT

12:15 - 12:15 **49P - The metastatic potential of grade 1 breast carcinoma of no special type: a deep insight into putative molecular mechanisms**

F. Lessi[1], C. Scopelliti[1], P. Aretini[1], M. Menicagli[1], S. Franceschi[1], C. Mazzanti[1], A. Naccarato[2], C. Scatena[2]; [1]San Giuliano Terme, IT, [2]Pisa, IT

12:15 - 12:15 **50P - ER pathway activity score as a predictive biomarker to improve stratification for neoadjuvant endocrine therapy**

D. Keizer[1], M. Inda[1], D. Clout[1], A. van de Stolpe[1], A. Fernando[2], C. Martinez-Perez[2], J.M. Dixon[2], A. Sims[2], A. Turnbull[2]; [1]Eindhoven, NL, [2]Edinburgh, GB

12:15 - 12:15 **51P - Higher ER load is not associated with better outcome in stage 1-3 breast cancer.**

I. Noordhoek[1], A. de Groot[1], D. Cohen[1], G.-J. Liefers[1], J. Portielje[2], J. Kroep[1]; [1]Leiden, NL, [2]The Hague, NL

12:15 - 12:15 **52P - The early changes of ΔSUV is a predictive marker of response and outcome in everolimus treated patients with mBC**

M. Sirico, Rome, IT

12:15 - 12:15 **53P - Activity of chemotherapy drugs in patient-derived xenografts (PDXs) from chemotherapy naïve local-regional triple negative breast cancer (LR-TNBC) patients**

M. Martín, R. Ramos-Medina, J.Á. Garcia Sáenz, M. del Monte-Millán, M. Cebollero, F. Moreno, I. Echavarria, Y. Jerez, T. Massarrah, S. Lopez-Tarruella Cobo; Madrid, ES

12:15 - 12:15 **54P - Prognostic and predictive value of phosphorylated HER2, HER3 and PTEN expression in patients with HER2-positive breast cancer treated with trastuzumab**

S. Debska-Szmich, R. Kusinska, M. Krakowska, R. Czyzykowski, U. Czernek, A. Zadrozna, P. Potemski; Lodz, PL

12:15 - 12:15 **55P - Tryptophan catabolism differentiates breast cancer patients from healthy controls but does not predict outcome**

C.E. Onesti, F. Boemer, C. Josse, S. Leduc, C. Poulet, V. Bours, G. Jerusalem; Liège, BE

12:15 - 12:15 **56P - HER2-targeted antibody dependent cell-mediated cytotoxicity (ADCC) mediated by NK cells against tyrosine kinase inhibitor (TKI)-treated breast cancer (BC) cell lines.**

D. Collins, N. Gaynor, N. Conlon, N. O'Donovan, J. Crown; Dublin, IE

12:15 - 12:15 **57P - Prognostic role of microRNA 182 and microRNA 18a in locally advanced triple negative breast cancer**

R. Bajaj[1], D. Doval[2], R. Tripathi[2], T. Sridhar[3], A. Korlimarla[3], K.D. Choudhury[1], M. Suryavanshi[1], A. Mehta[1]; [1]New Delhi, IN, [2]Delhi, IN, [3]Bangalore, IN

12:15 - 12:15 **58P - Spindle cell carcinoma of the breast: Rare cancer with potentially targetable biomarkers**

Z. Gatalica[1], S. Vranic[2], P. Stafford[1], J. Palazzo[3], F. Skenderi[2], J. Swensen[1], J. Xiu[1], D. Spetzler[1]; [1]Phoenix, US, [2]Sarajevo, BA, [3]Philadelphia, US

12:15 - 12:15 **59P - Myeloid derived-suppressor cells in healthy women and in advanced breast cancer patients.**

N. Palazon Carrion, M. Sánchez León, C. Jiménez Cortegana, F. Valdivia García, I. Araujo Fernández, F. Henao Carrasco, M. Nieto García, V. Sánchez Margalet, L. de la Cruz Merino; Sevilla, ES

12:15 - 12:15 **60P - Anti-inflammatory treatment and inhibition of B-cell activation in a nude mouse model of human breast cancer**

F. Fernandez Madrid, M.-C. Maroun, M. Long; Detroit, US

12:15 - 12:15 **61P - Founder mutations BRCA2 c.156_157insAlu in Portuguese Population**

F. Macedo, R. Félix Soares, T. Cunha Pereira, A.R. Monteiro, N. Bonito, S. Broco, T. Carvalho, M. Mariano, G. Sousa; Coimbra, PT

12:15 - 12:15 **62P - Growth inhibition of triple-negative breast cancer cells due to the lack of CD73**

N. Petruk[1], J. Sandholm[1], J. Tuomela[1], K. Selander[2]; [1]Turku, FI, [2]Oulu, FI

12:15 - 12:15 **63P - Controlling Nutritional Status (CONUT) score is a prognostic factor in patients with resected breast cancer**

W. Li, Q. Zhou; Chengdu, CN

12:15 - 12:15 **64P - Identification of serum proteome signatures of male breast cancer**

E. Zografos, A. Anagnostopoulos, A. Papadopoulou, E. Legaki, F. Zagouri, E. Marinos, G. Tsangaris, M. Gazouli; Athens, GR

12:15 - 12:15 **65P - miR-210 and miR-152 as biomarkers in Invasive Ductal Carcinoma by liquid biopsy**

D.A. Zuccari, B. Lopes, F. Ventura, J. Oliveira, C. Braga, E. Kato-Junior, N. Bordin-Junior; Sao Jose Do Rio Preto, BR

12:15 - 12:15 **66P - Dual targeting of RANKL/RANK pathway and HER-2 as a novel treatment strategy in HER-2 positive (+) breast carcinomas (BC)**

I. Zoi[1], E. Xingi[1], D. Thomaidou[1], A. Papavassiliou[2], M. Karamouzis[3]; [1]Athens, GR, [2]Athens, Attiki/GR, [3]Kolonaki, Athens/GR

12:15 - 12:15 **67P - Differential regulation of glucocorticoid receptor signaling in luminal, triple negative and HER2+ breast cancer cells**

E. Zhidkova, V. Maksimova, E. Lylova, A. Savinkova, K. Kuzin, K. Kirsanov, M. Yakubovskaya, E. Lesovaya; Moscow, RU

12:15 - 12:15 **68P - Functional CRISPR knockout screens for modifiers of sensitivity to trastuzumab emtansine**

B. Lipert[1], K. Siemens[1], A. Khan[1], H. Barker[1], P. Tsai[1], T. Ketela[2], S. Bohlander[1], C. Print[1], S. Jamieson[1], F. Hunter[1]; [1]Auckland, NZ, [2]Toronto, CA

12:15 - 12:15 **69P - Long duration of breastfeeding is associated to inflammatory breast (IBC) cancer**

M. Nesrine, H. El Benna, H. Rachdi, S. Labidi, H. Boussen; Ariana, TN

12:15 - 12:15 **70P - Long non-coding RNA PART1 contributes to cell proliferation and stem cell maintenance in triple-negative breast cancer**

B. Cruickshank, D. Vidovic, M. Dahn, M. Sultan, P. Marcato; Halifax, CA

12:15 - 12:15 **72P - Clinico-pathological relationship between androgen receptor (AR) and tumor infiltrating lymphocytes (TILs) in triple negative breast cancer (TNBC)**

H. Ibrahim, M. Alorabi, T. Helal, A. Aref, M. Kelany, L. Eid Abdallah, F. Sayed, D. Ali, D. Zaki, M. Ahmed; Cairo, EG

12:15 - 12:15 **74P - Inflammatory breast cancer cells are characterized by abrogated TGFβ1-dependent cell motility and SMAD3 activity.**

C. Rypens[1], C. Van Berckelaer[2], C. Billiet[2], J. Hauspy[2], F. Bertucci[3], G. Devi[4], P. Vermeulen[2], L. Dirix[2], S. Van Laere[5]; [1]Antwerpen, BE, [2]Wilrijk, BE, [3]Marseille, FR, [4]Durham, US, [5]Antwerp, BE

12:15 - 12:15 **76P - Prognostic and predictive significance of the expression of the beta-2 adrenergic receptor in HER2-positive breast cancer**

F. Richard, R. Bitton, C. Sotiriou, E. de Azambuja; Brussels, BE

12:15 - 12:15 **77P - Hep Par 1 Immunohistochemistry in Glycogen-Rich Clear Cell Carcinoma of the Breast**

M. Chang[1], J. Wu[2], G. Bethune[3]; [1]Burlington, US, [2]Toronto, CA, [3]Halifax, CA

12:15 - 12:15 **78P - an in vivo genome-wide RNAi screen identifies novel mediators of paclitaxel response in breast cancer**

M. Sultan, B. Cruickshank, T. Huynh, E. Lamoureux, D. Vidovic, M. Dahn, C. Giacomantonio, M. Langille, P. Marcato; Halifax, CA

12:15 - 12:15 **79P - The adipokine receptor CAP1 regulates breast cancer cell proliferation**

M. Bergqvist[1], S. Borgquist[2], A. Rosendahl[1]; [1]Lund, SE, [2]Aarhus, DK

12:15 - 12:15 **80P - DNA methylation markers of breast cancer response to anthracycline based neoadjuvant chemotherapy.**

V. Sigin[1], V. Strelnikov[1], N. Litviakov[2], O. Simonova[1], I. Volodin[1], E. Slonimskaya[2], A. Tanas[1], D. Zaletaev[1], E. Kuznetsova[1], M. Tsyganov[2]; [1]Moscow, RU, [2]Tomsk, RU

12:15 - 12:15 **81P - Inotilone interferes with chromosome replication as an attractive anti-cancer drug target for breast cancer**

L.-C. Chen[1], S.-H. Tu[2], Y.-S. Ho[2]; [1]New Taipei City, TW, [2]Taipei, TW

12:15 - 12:15 **82TiP - SCAN-B-rec: Infrastructure, technology and clinical research platform to profile and monitor metastatic breast cancer.**

A. Bosch, A.-M. Larsson, K. Holm, Å. Borg, J. Staaf, L. Saal; Lund, SE

12:15 - 12:15 **83TiP - RESCUE: Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer - A prospective non-interventional study on risk assessment by the EndoPredict test and long-term patient outcome in early luminal breast cancer**

J. Ettl[1], J.-U. Blohmer[2], C. Denkert[3], L. Beier[2], E. Klein[4], P. Neuser[3], M. Keller[2], M. Untch[2], M. Wittenberg[3], M. Kiechle[4]; [1]Munich, DE, [2]Berlin, DE, [3]Marburg, DE, [4]München, DE

12:15 - 12:15 **84TiP - HER-Seq: a blood-based genomic screening study to identify HER2 mutation-positive patients for enrollment into clinical trials with the pan-HER inhibitor neratinib**

Z. Tomasevic[1], L. Smyth[2], C. Saura[3], V. Boni[4], J. Garcia-Sáenz[4], A. Prat[3], L. Eli[5], S. Garza[5], A. Lalani[5], J. Crown[2]; [1]Belgrade, RS, [2]Dublin, IE, [3]Barcelona, ES, [4]Madrid, ES, [5]Los Angeles, US

12:15 - 12:15 **85TiP - Phase II trial of HER2-PET/CT using 68Ga-anti-HER2 VHH1 for characterization of HER2 presence in brain metastases of breast cancer patients**

M. Keyaerts, C. Xavier, H. Everaert, I. Vaneycken, C. Fontaine, L. Decoster, M. Vanhoeij, V. Caveliers, T. Lahoutte; Brussels, BE

12:15 - 12:15 **Early breast cancer: Adjuvant therapy**

12:15 - 12:15 **94P - Cholesterol-lowering medication: Impact on the clinical effect of adjuvant endocrine treatment in postmenopausal breast cancer**

K. Harborg[1], U. Heide-Jørgensen[2], T.P. Ahern[3], M. Ewertz[4], D. Cronin Fenton[2], S. Borgquist[1]; [1]Aarhus, DK, [2]Aarhus C, DK, [3]Burlington, US, [4]Odense C, DK

12:15 - 12:15 **95P - The changing role of gene-expression profiling in the era of de-escalating adjuvant chemotherapy in Early Stage Breast Cancer**

J. Steenhoven[1], A. Kuijer[2], K. Schreuder[1], S. Elias[1], P. Diest[1], E. Wall[1], S. Siesling[1], T. Dalen[1]; [1]Utrecht, NL, [2]Nieuwegein, NL

12:15 - 12:15 **96P - Adjuvant radiotherapy induces secondary tumor events in breast cancer patients with Li-Fraumeni Syndrome**

K. Rounis[1], T. Koukaki[2], C. Christodoulou[3], C. Papadimitriou[3], D. Tryfonopoulos[3], D. Mavroudis[1], S. Aggelaki[1], F. Fostira[4], E. Saloustros[5]; [1]Heraklion, GR, [2]Alexandroupolis, GR, [3]Athens, GR, [4]Athens, Agia Paraskevi/GR, [5]Larissa, Crete/GR

12:15 - 12:15 **97P - Adjuvant Herceptin in stage I breast cancer with the tumour size < 1 cm: our centre experience.**

H. Belikova, A. Alhasso; Glasgow, GB

12:15 - 12:15 **98P - Adjuvant management of male breast cancer in Bulgaria**

A. Konsoulova-Kirova[1], A. Yordanov[2], D. Kostova-Lefterova[3], S. El Shemeri[1], M. Dimova[1], S. Strashilov[2], R. Hristova[1], S. Maslyankov[3], Y. Marincheva[4], M. Vasileva[3]; [1]Varna, BG, [2]Pleven, BG, [3]Sofia, BG, [4]Burgas, BG

12:15 - 12:15 **99P - Talking about Risk in the Context of Genomic Tests (TARGET): evaluation of an educational program**

V. Jenkins, L. Fallowfield; Brighton, GB

12:15 - 12:15 **100P - Improved Survival of Young Patients with Breast Cancer ≤ 40 years of Age at Diagnosis**

J. El Dick, L. Khalil, M. Charafeddine, P. El Tomb, J. Fares, N. El Saghir; Beirut, LB

12:15 - 12:15 **101P - Breast Cancer in Young Women - a multi-center 10-year experience**

I. Eiriz[1], N. Pereira[2], M. Neves[2], M. Batista[2], T. Tomás[2], S. Braga[2]; [1]Amadora, PT, [2]Lisboa, PT

12:15 - 12:15 **102P - Breast cancer early recurrences in young women**

S. CIMA[1], E. Cekani[2], M. Valli[1], A. Richetti[1]; [1]Bellinzona, CH, [2]Tirana, AL

12:15 - 12:15 **103P - Anti HER-2 therapies and left ventricular dysfunction. A prospective study**

A. DANIELE, V. Gregorietti; Caba, AR

12:15 - 12:15 **104P - Final results of scalp cooling for hair preservation: A single-institution prospective study**

D. Loparco, L. Orlando, M. Caloro, C. Chiara, A. Quaranta, P. Schiavone, P. Fedele, M. Rendini, V. Bonuso, S. Cinieri; Brindisi, IT

12:15 - 12:15 **105P - Safe chemotherapy for treating early breast cancer in G6PD-deficient patients**

C. Donisi, F. Atzori, M. Dessì, M. Persano, M. Scartozzi; Cagliari, IT

12:15 - 12:15 **106P - Molecular sub types of breast cancer in a developing country. Classification immunohistochemical:Clinicopathologic feature and survival analysis**

H. Castro, L. Salazar, L. Garcia, N. Castro Sanchez, P. Ramos, K. Cruz; Guatemala, GT

12:15 - 12:15 **107P - A comparative study of Voluntary deep inspiration breath hold versus Free breathing techniques in adjuvant left breast hypofractionated radiotherapy.**

E. Elkhouly[1], N. Abdelbarry[2], Y. Rashed[2], A. Alhanafy[2], N. Shabaan[2]; [1]Shebin El Kom, Menoufia Governorate/EG, [2]Shebin El Kom, EG

12:15 - 12:15 **Early breast cancer: Neoadjuvant therapy**

12:15 - 12:15 **109P - Early Prediction of Non-pCR Using Ultrasound-Guided Serial Core Needle Biopsy in HER2-Positive Breast Cancer Patients**

Y. Zhang, J. Shen, Y. Zhou, Z.-M. Shao, G. Liu; Shanghai, CN

12:15 - 12:15 **110P - Evaluation of pathological complete response as a trial-level surrogate for long-term survival outcomes among triple-negative breast cancer patients receiving neoadjuvant therapy**

M. Huang[1], C. Qi[2], S. Ramsey[3], A. Briggs[4], J. Zhao[1], A. Haiderali[5], V. Karantza[5], J. Xie[6], C. Gu[6], P.A. Fasching[7]; [1]North Wales, US, [2]Boston, US, [3]Seattle, US, [4]Glasgow, GB, [5]Kenilworth, US, [6]Los Angeles, US, [7]Erlangen, DE

12:15 - 12:15 **111P - Subtype-guided 18F-FDG PET/CT in tailoring axillary surgery among node-positive breast cancer patients treated with neoadjuvant chemotherapy: A feasibility study**

S. Wu, Y. Wang, J. Li, N. Zhang, M. Mo, J. Shen, J. Cheng, G. Liu; Shanghai, CN

12:15 - 12:15 **112P - Nomogram for predicting axillary lymph node pathological complete response after neoadjuvant chemotherapy in node-positive breast cancer patients**

W. Wang, X. Wang, J. Liu, X. Wang; Beijing, CN

12:15 - 12:15 **113P - The aromatase inactivator exemestane suppresses serum leptin levels significantly in vivo - in contrast to the aromatase inhibitor letrozole**

N. Bahrami[1], S. Jabeen[1], T. Sauer[1], V. Kristensen[1], J. Gundersen[1], J. Geisler[2]; [1]Lorenskog, NO, [2]Oslo, NO

12:15 - 12:15 **114P - The incidence of metastases detected on a staging CT scan prior to neoadjuvant chemotherapy in early stage breast cancer**

R. Broadbent, S. Ralston, A. Armstrong, C. O'Brien, A. Wardley, G. Wilson, S. Howell; Manchester, GB

12:15 - 12:15 **115P - Pathological complete response rates following neoadjuvant systemic therapy in 300 patients with early or locally advanced HER2 positive breast cancer: the Royal Marsden experience.**

N. Kebaier Ep Chaabouni[1], N. Battisti[2], V. True[1], N. Chopra[1], S. Shepherd[1], K. Lee[1], R. Joshi[1], M. Kabir[1], M. Allen[1], A. Ring[1]; [1]London, GB, [2]Sutton, Surrey/GB

12:15 - 12:15 **116P - Study of Pathological Complete Response Rates with Neoadjuvant Concurrent Chemoradiation with Paclitaxel in Locally Advanced Breast Cancer**

P. Iyer[1], V. Radhakrishnan[2], A. Balasubramanian[1], V. Sridevi[1], A. Krishnamurthy[1], S. Ganesharaja[1]; [1]Chennai, IN, [2]New Delhi, IN

12:15 - 12:15 **117P - The prognostic and predictive role of the androgen receptor in TNBC treated with neo-adjuvant chemotherapy.**

L. Jongen, G. Floris, A. Laenen, J. Ardui, A. Smeets, I. Vergote, P. Berteloot, H. Wildiers, P. Neven; Leuven, BE

12:15 - 12:15 **118P - Dose dense neoadjuvant and adjuvant chemotherapy in triple-negative breast cancer patients: Survival analysis**

A. Kr, Bangalore, Karnataka/IN

12:15 - 12:15 **119P - A systematic review of endocrine deprivation therapy administered in the neoadjuvant setting in double positive breast cancer.**

M. Smith, P. Doran, C. Kelly, J. McCaffrey, S. Vencken, D. Wallace; Dublin, IE

12:15 - 12:15 **120P - Pathological complete response in early breast cancer patients undergoing neoadjuvant chemotherapy: Focus on Ki-67 and molecular subtypes**

B. Rapoport[1], J. Barnard-Tidy[2], R. Van Eeden[1], T. Smit[1], S. Nayler[3], C. Benn[3]; [1]Sandton, ZA, [2]Johannesburg, Gauteng/ZA, [3]Johannesburg, ZA

12:15 - 12:15 **121TiP - KEYNOTE-756: Randomized, double-blind, phase III study of pembrolizumab vs placebo + neoadjuvant chemotherapy (CT) and adjuvant endocrine therapy (ET) for high-risk, early-stage estrogen receptor–positive human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer (BC)**

F. Cardoso[1], L. Jia[2], K. Hirshfield[2], V. Karantza[2]; [1]Lisbon, PT, [2]Kenilworth, US

12:15 - 12:15 **122TiP - GeparDouze/NSABP B-59: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo.**

S. Loibl[1], C. Jackisch[2], P. Rastogi[3], S. Seiler[1], P. Lucas[3], C. Denkert[4], J. Costantino[3], V. Nekljudova[1], N. Wolmark[3], C. Geyer[5]; [1]Neu-Isenburg, DE, [2]Offenbach Am Main, DE, [3]Pittsburgh, US, [4]Marburg, DE, [5]Richmond, US

12:15 - 12:15 **Early breast cancer: Surgery and radiotherapy**

12:15 - 12:15 **124P - Late-term effects in the arm and shoulder with hypofractionated regional nodal irradiation in patients with breast cancer**

B. Yadav, A. Bansal, G. Philip; Chandigarh, IN

12:15 - 12:15 **125P - Brazilian randomized study: Impact of preoperative magnetic resonance in the evaluation for breast cancer conservative surgery (BREAST-MRI Trial)**

B. Mota, Y. Reis, M. Doria, M. Ricci, C. Shimizu, V. Ferreira, T. Tucunduva, N. de Barros, E. Baracat, J.R. Filassi; Sao Paulo, BR

12:15 - 12:15 **126P - Clinical outcome of early stage breast cancer patients with 1 to 3 positive axillary lymph nodes: A single institution experience**

A. ARJUNAN, S. Abbas, P. George; Thiruvananthapuram (trivandrum), IN

12:15 - 12:15 **127P - Treatment outcomes after post-operative radiotherapy in triple-negative breast cancer: multi-institutional retrospective study (KROG 17-05)**

J.H. Kim[1], S. Byun[1], K.H. Shin[1], D.-Y. Kim[2], T.H. Kim[3], Y.B. Kim[2], S.-Y. Lee[4], K. Kim[2]; [1]Daegu, KR, [2]Seoul, KR, [3]Goyang, KR, [4]Jeon Ju, KR

12:15 - 12:15 **128P - Role of short-course radiotherapy in post-operative carcinoma of the breast**

M. Behera[1], K. Mittal[2], S. Dutta[3], F. Ansari[4]; [1]Cuttack, Delhi/IN, [2]Eta, IN, [3]Siliguri, West Bengal/IN, [4]Delhi, IN

12:15 - 12:15 **129P - Perioperative factors and complications after delayed reconstruction in breast cancer patients in relation to outcome**

H. Dillekås, C. Kristoffersen, S.A. Jensen, O. Straume; Bergen, NO

12:15 - 12:15 **130P - Intraoperative radiotherapy with electronic brachytherapy system in breast cancer patients: Systematic review**

M. Vasileva[1], D. Kostova-Lefterova[2], S. Maslyankov[1], T. Paycheva[1], A. Vlahova[1], Z. Zahariev[1], V. Pavlov[1], G. Todorov[1], K. Angelov[1], A. Konsoulova[3]; [1]Sofia, BG, [2]Pleven, BG, [3]Burgas, BG

12:15 - 12:15 **131P - A prospective comparative study of sentinel lymph node biopsy with indo-cyanine green (ICG) florescence technique versus dual dye technique for early breast cancer: Going beyond the horizon**

A. Kr[1], S. Sp[2], R. Kumar[2]; [1]Bangalore, Karnataka/IN, [2]Bangalore, IN

12:15 - 12:15 **132P - Surgical management of breast cancer in BRCA mutation carriers: A single centre experience**

A. Fachinetti[1], C. Chiappa[2], S. Vischi[1], R. Roesel[1], L. Ambrosiani[1], I. Carnevali[2], M.G. Tibiletti[2], F. Rovera[2]; [1]Como, IT, [2]Varese, IT

12:15 - 12:15 **133P - A nomogram for predicting the malignant diagnosis of BI-RADS US category 4A lesions in women with dense breast tissue**

Y. Yang, Y. Hu, S. Shen, X. Jiang, H. Wang, R. Gu, F. Liu, H. Jia, C. Gong, Q. Liu; Guangzhou, CN

12:15 - 12:15 **134P - The negative pressure therapy with PICO as a prevention of surgical site infection in high risk patients undergoing breast surgery**

T. Fogacci, F. Cattin, D. Samorani; Santarcangelo Di Romagna, IT

12:15 - 12:15 **135P - Multi-gene panel testing at the hereditary breast and ovarian cancer (HBOC) unit of the Hospital Clinic of Barcelona**

B. Adamo, L. Moreno, L. Gaba, M. Vidal, T. Pascual, N. Chic, I. Alonso, J.A. Puig-Butillé, M. Muñoz, A. Prat; Barcelona, ES

12:15 - 12:15 **136P - Decisions for immediate breast reconstruction. Do surgeons make sensible choices?**

M. Zaidi, M. Rezacova, L. Mansfield, S. Helme, C. Yiangou, A. Agrawal; Portsmouth, GB

12:15 - 12:15 **137P - Can Sentinel Node Biopsy be Considered in Early Breast Cancer with Axillary Nodal Disease?**

P. May-Miller, M. Zaidi, S. Helme, L. Mansfield, C. Yiangou, A. Agrawal; Portsmouth, GB

12:15 - 12:15 **138P - Efficacy of using imprint and exfoliative cytology followed by frozen section as intraoperative margin assessment in breast conservation surgery**

T. Tamanuki, M. Namura, T. Aoyagi, S. Shimizu, T. Suwa, H. Matsuzaki; Funabashi, JP

12:15 - 12:15 **139P - Rate of Breast-Conserving Surgery vs Mastectomy in Developing countries**

A. Kr[1], S. Sp[2], R. Kumar[2]; [1]Bangalore, Karnataka/IN, [2]Bangalore, IN

12:15 - 12:15 **140P - Evaluation of Intraoperative Frozen Section with Final Histopathology Results for Sentinel Lymph Node Biopsy in Breast Cancer**

A. Kr[1], S. Sp[2], R. Kumar[2]; [1]Bangalore, Karnataka/IN, [2]Bangalore, IN

12:15 - 12:15 **141P - Implant-based Breast Cancer Reconstruction with Biological Matric or Synthetic Mesh**

A. Sukhotko, A. Zikiryahodjaev, M. Ermoshchenkova, I. Shirokih, A. Tukmakov; Moscow, RU

12:15 - 12:15 **142P - Relapse after radical subcutaneous mastectomy with simultaneous reconstruction in patients with breast cancer**

E. Rasskazova, A. Zikiryakhodzhaev, S. Khakimova; Moscow, RU

12:15 - 12:15 **143P - A systemic review of information requirements of young women with breast cancer undergoing mastectomy or breast conserving surgery**

T. Mehmood, Lahore, PK

12:15 - 12:15 **Immunotherapy**

12:15 - 12:15 **144P - Immune Cell Dynamics Induced by a Single Dose of Pembrolizumab as Revealed by Single-Cell RNA profiling**

H. Vos[1], A. Bassez[1], J. Qian[1], G. Floris[1], I. Nevelsteen[1], K. Lambein[2], P. Neven[1], H. Wildiers[1], D. Lambrechts[1], A. Smeets[1]; [1]Leuven, BE, [2]Gent, BE

12:15 - 12:15 **145P - Immune functions of follicular helper CD4+CXCR5+ T cells in human breast cancer**

M. Langouo Fontsa[1], G. Noel[1], R. de Wind[1], G. Van den Eynden[2], A. Boisson[1], C. Naveaux[1], D. Larsimont[1], S. Garaud[1], M. Piccart[1], K. Willard-Gallo[1]; [1]Brussels, BE, [2]Edegem, BE

12:15 - 12:15 **146P - Expression of immunomodulatory molecule,Programmed death ligand-1 in triple negative invasive breast cancer in the Indian population**

N. Gorijavolu[1], P. Augustine[2], L. Subhadra Devi[2], G. Antony[2], J. Kattoor[2], A. Mathew[2]; [1]Thiruvananthapuram, IN, [2]Thiruvananthapuram (trivandrum), IN

12:15 - 12:15 **147P - Clinical significance of BCL-2 with basal and non - basal triple negative breast cancer (TNBC)**

V. Srinivasalu[1], A. Susan[2], A. Philip[3], W. Jose[4], S. N V[5], A. Nambiar[2], K. Pavithran[4]; [1]Bangalore, IN, [2]Kochi, IN, [3]Cochin, Tamil Nadu/IN, [4]Kochi, Kerala/IN, [5]Cochin, IN

12:15 - 12:15 **148P - Investigation on the MyD88 mediated TLR3 signaling via cell surface in breast cancer**

A. Singh[1], A. Basu[2], R. Devkar[3]; [1]Bardhaman, IN, [2]Burdwan, IN, [3]Vadodara, IN

12:15 - 12:15 **Metastatic breast cancer**

12:15 - 12:15 **155P - Pooled efficacy analysis of first-line ribociclib (RIB) plus endocrine therapy (ET) in HR+/HER2– advanced breast cancer (ABC)**

D. Tripathy[1], G. Hortobagyi[1], A. Chan[2], S.-A. Im[3], S. Chia[4], D. Yardley[5], F. Esteva[6], S. Hurvitz[7], A. Ridolfi[8], D. Slamon[9]; [1]Houston, TX/US, [2]Nedlands, AU, [3]Seoul, KR, [4]Vancouver, CA, [5]Chattanooga, US, [6]New York, TX/US, [7]Santa Monica, CA/US, [8]Rueil-Malmaison, FR, [9]Los Angeles, CA/US

12:15 - 12:15 **156P - Palbociclib plus fulvestrant as first-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase 2 study**

A. Welt[1], M. Welslau[2], D. Lüftner[3], M. Deryal[4], R. Liersch[5], J. Sahlmann[6], L. Houet[6], C. Vannier[6], N. Marschner[6], K. Potthoff[6]; [1]Essen, DE, [2]Aschaffenburg, DE, [3]Berlin, DE, [4]Saarbruecken, DE, [5]Münster, DE, [6]Freiburg, DE

12:15 - 12:15 **157P - Differences between breast cancer subtypes in developing metastatic disease**

H. Wildiers, M. van Mechelen, A. van Herck, J.-P. Lobelle, A. Smeets, P. Neven, K. Punie; Leuven, BE

12:15 - 12:15 **158P - Intermittent versus continuous chemotherapy beyond first-line for patients with HER2-negative advanced breast cancer (BOOG 2010-02)**

F. Erdkamp[1], A. Claessens[1], M. Lopez-Yurda[2], J. Bouma[3], H. van Tinteren[2], J. Rademaker-Lakhai[2], A. Honkoop[4], H. de Graaf[5], V. Tjan-Heijnen[6], M. Bos[3]; [1]Sittard-Geleen, NL, [2]Amsterdam, NL, [3]Rotterdam, NL, [4]Zwolle, NL, [5]Leeuwarden, NL, [6]Maastricht, NL

12:15 - 12:15

159P - Influence on quality of life of chemotherapy scheduling for patients with advanced HER2-negative breast cancer

A. Claessens[1], R. Timman[2], J. Busschbach[2], J. Bouma[2], J. Rademaker-Lakhai[3], F. Erdkamp[1], V. Tjan-Heijnen[4], M. Bos[2]; [1]Sittard-Geleen, NL, [2]Rotterdam, NL, [3]Amsterdam, NL, [4]Maastricht, NL

12:15 - 12:15

160P - CDK 4/6 inhibitors plus endocrine therapy in ER positive metastatic breast cancer (MBC): Systematic review and meta-analysis of randomized clinical trials.

F. D'Avanzo[1], C. Saggia[1], V. Rossi[1], G. Siffredi[1], F. Barone Adesi[1], A. Gennari[2]; [1]Novara, IT, [2]Genova, IT

12:15 - 12:15

161P - BRCA status, treatment patterns and outcomes in HER2- Advanced Breast Cancer (ABC): A multi-country real-world study

A. Niyazov[1], R. Quek[2], K. Lewis[3], J. Kemp[3], A. Rider[4]; [1]New York, US, [2]San Francisco, US, [3]Cheshire, GB, [4]Bollington, GB

12:15 - 12:15

162P - Hospitalization and Supportive Care Medication (SCM) Utilisation in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in EMBRACA

J. Ettl[1], R. Quek[2], S. Hurvitz[3], A. Goncalves[4], I. Tudor[2], H. Rugo[5]; [1]Munich, DE, [2]San Francisco, US, [3]Santa Monica, CA/US, [4]Marseille, CEDEX 9/FR, [5]San Francisco, CA/US

12:15 - 12:15

163P - SAKK 21/12 - A stratified, multicenter Phase II trial of transdermal CR1447 in endocrine responsive-HER2 negative and triple negative-androgen receptor positive metastatic or locally advanced breast cancer

M. Vetter[1], K. Rothgiesser[2], Q. Li[2], H. Hawle[2], W. Schönfeld[3], K. Ribi[2], S. Riniker[4], R. von Moos[5], A. Müller[6], B. Thürlimann[4]; [1]Basel, CH, [2]Bern, CH, [3]Erlangen, DE, [4]St. Gallen, CH, [5]Chur, CH, [6]Winterthur, CH

12:15 - 12:15

164P - Locoregional therapy targeted at the primary tumour improves overall survival in patients with stage IV metastatic breast cancer: A systematic review and meta-analysis with 185942 patients

R. Gera, K. Mokbel, H. El Hage Chehade, U. Wazir, S. Tayeh; London, GB

12:15 - 12:15

165P - Prevalence of Risk Factors for QT Prolongation and Torsades de Pointes Among Women With HR+/HER2– Advanced or Metastatic Breast Cancer Treated in Real-World Settings in Italy and Germany

N. Harbeck[1], E. Law[2], M. Ajmera[3], D. Mitra[2], K. Davis[3], S. Brucker[4], M. De Laurentiis[5]; [1]Munich, DE, [2]New York, US, [3]Research Triangle Park, US, [4]Tübingen, DE, [5]Napoli, IT

12:15 - 12:15

166P - Pooled safety analysis of first-line ribociclib (RIB) plus endocrine therapy (ET) in HR+/HER2– advanced breast cancer (ABC)

D. Tripathy[1], G. Hortobagyi[1], A. Chan[2], S.-A. Im[3], S. Chia[4], D. Yardley[5], F. Esteva[6], S. Hurvitz[7], A. Ridolfi[8], D. Slamon[9]; [1]Houston, TX/US, [2]Nedlands, AU, [3]Seoul, KR, [4]Vancouver, CA, [5]Chattanooga, US, [6]New York, TX/US, [7]Santa Monica, CA/US, [8]Rueil-Malmaison, FR, [9]Los Angeles, CA/US

12:15 - 12:15

167P - Utilization and outcomes of Eribulin Mesylate POst a cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i): An observational real-World study in UnitEd States community oncology pRactices (EMPOWER)

S. Mougalian[1], E. Wang[2], K. Alexis[2], B. Feinberg[3], D. Nero[3], T. Miller[3], J. Laney[3], D. Chatterjee[2], R. Knoth[2], J. Kish[3]; [1]New Haven, US, [2]Woodcliff Lake, US, [3]Dallas, US

12:15 - 12:15

168P - Association of Serum IGF1 and Adiponectin in Prognosis of Breast Cancer Metastasis

S. Akter[1], M. Faruque[1], K. Nahar[2]; [1]Dhaka, BD, [2]

12:15 - 12:15

169P - Impact of BRCA1/2 mutations status on patient reported outcomes in HER2- advanced breast cancer: Results from a multi-country real-world study

A. Rider[1], R. Quek[2], K. Lewis[3], J. Kemp[3], A. Niyazov[4]; [1]Bollington, GB, [2]San Francisco, US, [3]Cheshire, GB, [4]New York, US

12:15 - 12:15

170P - Real world patterns of use and value of Pertuzumab in the treatment of HER2+ Metastatic Breast Cancer in Singapore: the National Cancer Centre Singapore experience

S. Rahardja, R.Y.C. Tan, R. Sultana, F.L. Leong, E. Lim; Singapore, SG

12:15 - 12:15

171P - Gastrointestinal Symptoms & Health-related Quality of Life Among Women With HR+/HER2– Advanced or Metastatic Breast Cancer Treated in Real-World Settings in Italy and Germany

S. Brucker[1], E. Law[2], M. Ajmera[3], D. Mitra[2], K. Davis[3], N. Harbeck[4], M. De Laurentiis[5]; [1]Tübingen, DE, [2]New York, US, [3]Research Triangle Park, US, [4]Munich, DE, [5]Napoli, IT

12:15 - 12:15

172P - Breast cancer specific graded prognostic assessment (BC-GPA) score and outcome of Her 2 positive breast cancer patients with brain metastases. A single centre retrospective analysis.

S. Kate, N. Paleja, R. Patil, S. Bhalerao, S. Dhande, V. Palve, M. Targe, R. Nagarkar, L. Fernandes; Nashik, IN

12:15 - 12:15

173P - Current treatment landscape in triple negative breast cancer: A systematic literature review

A. Fu[1], Y. Kuang[2], M. Fazeli[2], N. Kumar[3], C. Davis[1]; [1]Princeton, US, [2]Santa Monica, US, [3]Chapel Hill, US

12:15 - 12:15

174P - The outcome of patients with metastatic breast cancer with lung metastasis treated with fulvestrant is superior to that of those with liver metastasis

M. He, J.-J. Li, W.-J. Zuo, L. Ji, X.-C. Hu, Z.-H. Wang, Z.-M. Shao; Shanghai, CN

12:15 - 12:15

175P - A four-year study of epidemiological trends of breast cancer in a Haitian cancer program

J.J. Bernard, L.G. Alexis, V.J. Degennaro; Port-Au-prince, HT

12:15 - 12:15 **176P - Brain metastasis of Breast Cancer: a 10-year single institution retrospective analysis**

M. Vaz, T. Tomás, I. Eiriz, S. Almeida, M. Vitorino, G. Atalaia, A. del Rio, S. Braga; Amadora, PT

12:15 - 12:15 **177P - Pertuzumab (P) as ≥2nd-line therapy for HER2-positive metastatic breast cancer (mBC): Swiss clinical experience**

E. Biskup[1], C. Montavon Sartorius[1], A. Müller[2], C. Leo[3], C. Uhlmann Nussbaum[4], D. Koychev[5], A. Schreiber[6], C. Taverna[7], D. Thorn[1], M. Vetter[1]; [1]Basel, CH, [2]Winterthur, CH, [3]Baden, CH, [4]Olten, CH, [5]Rapperswil, CH, [6]Aarau, CH, [7]Muensterlingen, CH

12:15 - 12:15 **178P - Intrahepatic mitomycin C infusion in breast cancer liver metastases**

B. Aarts[1], E. Klompenhouwer[1], R. Dresen[2], A. Laenen[2], R. Beets-Tan[1], K. Punie[2], P. Neven[2], G. Maleux[2], H. Wildiers[2]; [1]Amsterdam, NL, [2]Leuven, BE

12:15 - 12:15 **179P - Regulation of MMP9 expression by human arylamine N-acetyltransferase (NAT1) via Hif-1a**

P. LI[1], R. Minchin[2], N. Butcher[2]; [1]St Lucia, AU, [2]Brisbane, AU

12:15 - 12:15 **180P - Palbociclib in daily clinical use – real world experience of the breast center at the University Hospital Munich**

A. Hester[1], A. Koenig[1], F. Dobler[1], T. Degenhardt[1], H. Heidegger-Steger[1], A.-G. Kurt[1], S. Kahlert[1], S. Mahner[2], N. Harbeck[2], R. Wuerstlein[2]; [1]München, DE, [2]Munich, DE

12:15 - 12:15 **181P - A nationwide, multi-institutional retrospective study of efficacy and safety of eribulin in Korean breast cancer patients(REMARK)**

J. Jeong[1], M.H. Park[2], S.J. Lee[3], W.C. Noh[1], C.W. Jeon[1], S.W. Lee[4], G.S. Son[5], B.I. Moon[1], J.S. Lee[6], S.S. Kang[1]; [1]Seoul, KR, [2]Hwasun-Gun, KR, [3]Daegu, KR, [4]Busan, KR, [5]Ansan, KR, [6]Daejeon, KR

12:15 - 12:15 **182P - Efficacy and Tolerability of Neratinib in Advanced HER-2 Positive Breast Cancer: a Single Institution Experience**

S. Shepherd[1], K. Lee[1], K. Mohammed[2], K. Patel[2], M. Allen[2], S. Johnston[1], M. Parton[1], A. Ring[2], N. Turner[1], A. Okines[1]; [1]London, GB, [2]Sutton, GB

12:15 - 12:15 **183P - CD146 suppresses breast tumor via its novel downstream signaling pathway, Latexin/Akt/NFκB**

A. Ouhtit[1], A. Fernando[2]; [1]Doha, QA, [2]Chicago, US

12:15 - 12:15 **184P - CAM-H2 effectively targets and treats HER2 positive brain lesions: a comparative preclinical study with Trastuzumab.**

J. Puttemans[1], M. D'Huyvetter[1], B. Windhorst[2], T. Lahoutte[1], N. Devoogdt[1]; [1]Brussels, BE, [2]Amsterdam, NL

12:15 - 12:15 **185P - Clinical, biological and histological features predictive of response to everolimus in metastatic breast cancer patients.**

V. Van den bossche[1], G. Jadot[1], D. Augusto[2], V. Samartzi[2], S. Castela[2], S. Lejeune[2], E. Seront[2]; [1]Woluwe-Saint-lambert, BE, [2]Haine Saint Paul, BE

12:15 - 12:15 **186P - HER2-positive breast cancer and CNS metastases: prognostic factors and clinical outcome**

E. Agostinetto, G. Masci, L. Giordano, A. Losurdo, R. De Sanctis, R. Torrisi, M. Zuradelli, M. Scorsetti, A. Santoro; Rozzano, IT

12:15 - 12:15 **187P - Sensitivity and dynamic range of CellSearch based CSF DTC enumeration in patients with breast cancer related leptomeningeal metastases (LM).**

A. Van Goethem[1], C. Rypens[2], A. Rutten[1], T. Van den Mooter[1], K. Erven[1], T. Van Havenbergh[1], A. Prové[1], S. Van Laere[3], P. Vermeulen[1], L. Dirix[1]; [1]Wilrijk, BE, [2]Antwerpen, BE, [3]Antwerp, BE

12:15 - 12:15 **188P - Efficacy of trastuzumab-emtansina (T-DM1) in HER2-positive breast cancer (BC) with brain metastases (BM): a single institution experience**

R. Martin Huertas, E. Lopez Miranda, E. Corral de la Fuente, J.J. Serrano Domingo, M. Fernandez Abad, N. Martinez, E.M. Guerra, A. Cortes Salgado, M. Gion Cortes, A. Carrato Mena; Madrid, ES

12:15 - 12:15 **189P - Bone seeking matrix metalloproteinase-2 (MMP-2) inhibitors can prevent bone metastatic breast cancer**

M. Tauro, C. Lynch; Tampa, US

12:15 - 12:15 **190P - Non-vigorous physical activity and the risk of breast cancer among Nigerian women**

S. Azubuike, L. Hayes, R. McNally; Newcastle Upon Tyne, GB

12:15 - 12:15 **191P - Imaging-proven Venous Thromboembolism among Breast Cancer Patients in a Tertiary Hospital in the Philippines from 2010-2015**

A.T. Gerona, A. Gorospe; Quezon City, PH

12:15 - 12:15 **192P - Predictive role of derived neutrophil to lymphocyte ratio on platinum-based chemotherapy in triple-negative breast cancer**

A. Marra[1], G. Viale[1], D. Trapani[1], E. Nicolò[1], S. Morganti[2], A. Esposito[1], I. Minchella[1], C. Criscitiello[1], G. Curigliano[1], M. Locatelli[1]; [1]Milan, IT, [2]Milan, Piacenza/IT

12:15 - 12:15 **193P - PALBOCOMP: Retrospective observational analysis of palbociclib treatment in patients with advanced breast cancer within a compassionate use program in Spain**

L. Manso[1], B. Bermejo[1], I. Delgado[2], E. Aguirre[3], A. Oltra[4], M. Gonzalez[5], D. Malón[1], J.E. Ales[6], C. Rodriguez[7], F. Moreno[1]; [1]Madrid, ES, [2]Badajoz, ES, [3]Zaragoza, ES, [4]Alcoy, ES, [5]Barcelona, ES, [6]Ávila, ES, [7]Salamanca, ES

12:15 - 12:15 **194TiP - Phase 3 study of [fam-] trastuzumab deruxtecan (DS-8201a) vs T-DM1 for HER2-positive breast cancer**

S. Verma[1], J. Shahidi[2], C. Lee[3], K. Wang[2], J. Cortes[4]; [1]Calgary, CA, [2]Basking Ridge, US, [3]Edison, US, [4]Madrid, ES

12:15 - 12:15 **195TiP - SYNERGY: Phase I and randomized phase II trial to investigate the addition of the anti-CD73 antibody oleclumab to durvalumab, paclitaxel and carboplatin for previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)**

C. Maurer[1], D. Eiger[2], C. Velghe[2], P. Aftimos[2], M. Maetens[2], J. Gaye[2], M. Paesmans[2], M. Ignatiadis[2], M. Piccart[2], L. Buisseret[2]; [1]Köln, DE, [2]Brussels, BE

12:15 - 12:15 **196TiP - SGNLVA-002: Single Arm, Open Label, Phase 1b/2 Study of Ladiratuzumab Vedotin (LV) in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer**

V. Boni[1], C. Alemany[2], J. Meisel[3], R. Sinha[3], D. Sterrenberg[4], K. Tkaczuk[5], Y. Wang[6], Z. Wang[6], H. Han[6]; [1]Madrid, ES, [2]Orlando, US, [3]Atlanta, US, [4]Harvey, US, [5]Baltimore, US, [6]Bothell, US

12:15 - 12:15 **197TiP - Phase 3 study of [fam-] trastuzumab deruxtecan vs investigator's choice in T-DM1-pretreated HER2+ breast cancer**

F. André[1], J. Shahidi[2], C. Lee[3], K. Wang[2], I. Krop[4]; [1]Villejuif, FR, [2]Basking Ridge, US, [3]Edison, US, [4]Boston, US

12:15 - 12:15 **198TiP - A Randomized, Double-Blinded, Controlled Study of Tucatinib (ONT-380) vs. Placebo in Combination with Capecitabine (C) and Trastuzumab (T) in Patients with Pretreated HER2+ Unresectable Locally Advanced or Metastatic Breast Carcinoma (mBC) (HER2CLIMB)**

E. Paplomata[1], T. Bachelot[2], V. Mueller[3], C. Murias[4], R. Murthy[5], A. Okines[4], A. Wardley[6], L.N. Walker[7], A.M. Antunes De Melo e Oliveira[8]; [1]Atlanta, US, [2]Lyon, CEDEX/FR, [3]Hamburg, DE, [4]London, GB, [5]Houston, US, [6]Manchester, GB, [7]Seattle, US, [8]Barcelona, ES

12:15 - 12:15 **Supportive care and survivorship**

12:15 - 12:15 **200P - Noninvasive and low-cost technique for early detection of clinically relevant breast lesions using a handheld point-of-care medical device (iBreast): prospective three-arm triple-blinded comparative study for breast cancer screening in low resource setting countries**

A. Kr, Bangalore, Karnataka/IN

12:15 - 12:15 **201P - Preventive Bilateral Mastectomy (PBS) in BRCA Mutation Carriers with Ovarian Cancer: is it Justified?**

T. Safra[1], B. Waissengrin[1], D. Gerber[2], R. Bernstein-Molcho[3], R. Shaizaf[1], J. Taff[2], F. Mugia[2], M. Frey[2]; [1]Tel Aviv, IL, [2]New York, US, [3]Ramat Gan, IL

12:15 - 12:15 **202P - Adherence to Dietary Guidelines (DG) and Body Weight Change (BWC) in Early-stage Breast Cancer (EBC): a prospective trial in patients submitted to nutrition evidence-based educational intervention.**

L. Carbognin[1], I. Trestini[1], I. Sperduti[2], E. Fiorio[1], D. Tregnago[1], S. Pilotto[1], G. Scambia[2], G. Tortora[2], M. Milella[1], E. Bria[2]; [1]Verona, IT, [2]Roma, IT

12:15 - 12:15 **203P - The analysis of statistics of breast cancer in Cherkassy region before and after Chernobyl disaster**

L. Zrelykh, Kiev, UA

12:15 - 12:15 **204P - Increased risk of breast cancer-specific mortality among women with second primary breast cancer: A SEER population-based study**

W. Chengshi[1], K. Hu[2], H. Zheng[1], D. Lu[2]; [1]Chengdu, CN, [2]Stockholm, SE

12:15 - 12:15 **205P - A prospective, multicentre, randomized trial comparing vascular access strategies for patients receiving non-trastuzumab containing chemotherapy for early stage breast cancer**

A. Awan[1], B. Basulaiman[2], A. Robinson[3], C. Stober[2], D. Fergusson[2], A.A. Joy[4], L. Vandermeer[2], R. Mallick[2], D. Saunders[2], M. Clemons[2]; [1]Montreal, CA, [2]Ottawa, CA, [3]Kingston, ON/CA, [4]Edmonton, Alberta/CA

12:15 - 12:15 **206P - Protroca: a non-interventional study on prophylaxis of chemotherapy induced neutropenia using Lipegfilgrastim in non-selected breast cancer patients**

R. Wuerstlein[1], N. Harbeck[1], E.-M. Grischke[2], D. Forstmeyer[3], R. von Schumann[4], P. Krabisch[5], U. Nitz[4], O. Gluz[4], R. Kates[6], M. Graeser[7]; [1]Munich, DE, [2]Tübingen, DE, [3]Leipzig, DE, [4]Mönchengladbach, DE, [5]Chemnitz, DE, [6]Otterfing, DE, [7]Monchengladbash, DE

12:15 - 12:15 **207P - After Breast Cancer : A Nurse Practitioner led Model of Care for Women on Adjuvant Endocrine Treatment**

T. Shenkier, C. Lohrisch, C. Simmons, A. Dotts, H. McTaggart-Cowan, E. Houlihan, C. Johnston, D. Le, K. Gelmon, S. Chia; Vancouver, CA

12:15 - 12:15 **208P - Second malignancies with breast cancer - an audit**

V. Srinivasalu[1], N. Subramaniam[2], S. K S[2], A. V[2], S. Kolathu[2], V.K. D K[2], A. Philip[3], W. Jose[4], B. Kunheri[2], K. Pavithran[4]; [1]Bangalore, IN, [2]Kochi, IN, [3]Cochin, Tamil Nadu/IN, [4]Kochi, Kerala/IN

12:15 - 12:15 **209P - Compromised cancer-specific survival among under-insured Chinese patients with breast cancer: a prospective cohort study**

Y. Xie[1], U. Valdimarsdóttir[2], Q. Gou[1], W. Chengshi[1], K. Hu[2], R. Tamimi[3], H. Zheng[1], D. Lu[2]; [1]Chengdu, CN, [2]Stockholm, SE, [3]Boston, US

12:15 - 12:15 **210P - Comparison of breast cancer outcomes in a private hospital with national outcomes in a country with a mixed public/private healthcare model.**

M. Killian, P. Walsh, D. O Connor, K. Murphy, B. Bird, C. Murphy; Cork, IE

12:15 - 12:15 **211P - A Cost-Utility Analysis of Administration Schedules of G-CSF for Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia in Early Stage Breast Cancer: Economic Evaluation alongside the REaCT-G Trial**

B. Basulaiman[1], A. Awan[2], J. Hilton[3], D. Fergusson[3], C. Stober[3], L. Vandermeer[3], D. Saunders[3], M. Clemons[3], K. Thavorn[3]; [1]Riyadh, SA, [2]Montreal, CA, [3]Ottawa, CA

12:15 - 12:15 **212P - Patient-reported health problems and health care use after treatment for early breast cancer**

K. de Ligt[1], M. Heins[1], J. Verloop[1], C. Smorenburg[2], J. Korevaar[1], S. Siesling[1]; [1]Utrecht, NL, [2]Amsterdam, NL

12:15 - 12:15 **213P - HIV infection in breast cancer patients from Mozambique – a prospective cohort study**

M. Brandão[1], A. Guisseve[2], G. Bata[2], G. de Morais[2], M. Alberto[2], F. Schmitt[3], C. Lorenzoni[2], S. Tulsidás[2], N. Lunet[3], C. Carrilho[2]; [1]Brussels, BE, [2]Maputo, MZ, [3]Porto, PT

12:15 - 12:15 **214P - Trastuzumab related cardiotoxicity in nonmetastatic breast cancer: a real-world scenario**

S. Shrivastva[1], S. Prasad[2], R. Chennamaneni[2], B. Stalin[2], M. Konatam[1], S. Gundeti[2]; [1]Hyderabad, IN, [2]Hyderabad, Andhra Pradesh/IN

12:15 - 12:15 **215P - Male Breast Cancer, a heterogeneous entity - Experience from a Cancer Center**

J. Carvalho, M. Peixoto, T. Cunha Pereira, A.R. Garcia, M. Mariano, S. Broco, I. Pazos, T. Carvalho, J. Ribeiro, G. Sousa; Coimbra, PT

12:15 - 12:15 **216P - The predictive value of NHS PREDICT for triple negative breast cancer**

M. Sobocan, U. Belak, N. Sikošek Čas, N. Kozar, K.K. Krajnc, I. Takac, D. Arko; Maribor, SI

12:15 - 12:15 **217P - Feasibility of Quantitative Sensory Testing (QST) in clinical routine as a tool to evaluate chemotherapy-induced peripheral Neuropathy (CIPN) amongst breast cancer patients treated with taxanes.**

I. Ioannou[1], D. Utpadel-Fischler[2], T. Tölle[2], M. Kiechle[3], J. Ettl[2]; [1]Berlin, DE, [2]Munich, DE, [3]München, DE

12:15 - 12:15 **218P - Feasibility study of using an app-based mHealth group challenge to improve physical activity (PA) and fatigue after breast cancer (BC)**

E. Martin[1], A. Di Meglio[1], C. Charles[2], A. Ferreira[3], A. Gbenou[2], M. Blond[4], B. Fagnou[4], B. Pistilli[1], M. Saghatchian[5], I. Vaz-Luis[1]; [1]Villejuif, FR, [2]Villejuif Cedex, FR, [3]Lisbon, PT, [4]Nantes, FR, [5]Villejuif, CEDEX/FR

12:15 - 12:15 **219TiP - Feasibility of a self-screening for insomnia and acceptability of an online targeted video-based cognitive behavioral program in cancer outpatients: SLEEP-4-ALL-1 study design.**

C. CHARLES[1], D. Boinon[1], L. Fasse[1], J. Journiac[2], G. Pallubicki[1], G. Ninot[3], E. Ninot[3], S. Gouy[1], J. Savard[4], S. Dauchy[1]; [1]Villejuif, FR, [2]Boulogne-Billancourt, FR, [3]Montpellier, FR, [4]Laval, CA

13:00 - 14:00	**Type: Industry Satellite Symposium** **Title: F. Hoffmann-La Roche - Industry Satellite Symposium: Advances in triple-negative breast cancer care: ExCITing prospects in personalised cancer immunotherapy** Chair(s): Joseph Gligorov, FR	**Berlin Hall**
13:00 - 13:05	**Introduction and welcome** J. Gligorov, Paris, FR	
13:05 - 13:15	**Cancer immunotherapy: Recent advances in triple-negative breast cancer** T.-W. Park-Simon, Hannover, DE	
13:15 - 13:30	**PD-L1 as a biomarker in metastatic triple-negative breast cancer: Personalising patient treatment** G. Viale, Milan, IT	
13:30 - 13:55	**Interactive discussion and Q&A**	
13:55 - 14:00	**Summary and close** J. Gligorov, Paris, FR	

13:00 - 14:00	**Type: Industry Satellite Symposium** **Title: Daiichi-Sankyo - Industry Satellite Symposium: Targeting HER driven breast cancer - Emerging and future options** Chair(s): Fabrice André, FR	**Vienna Hall**

13:00 - 13:05 **Welcome & introduction**

F. André, Villejuif, FR

13:05 - 13:20 **Current progress in HER2 positive metastatic Breast cancer**

H. Rugo, San Francisco, CA/US

13:20 - 13:35 **Evolution of HER2-targeted therapies: The role of antibody drug conjugates**

F. André, Villejuif, FR

13:35 - 13:50 **The emerging treatment paradigm for HER driven breast cancer**

J. Cortes Castan, Barcelona, ES

13:50 - 14:00 **Q&A with speaker panel**

F. André[1], J. Cortes Castan[2], H. Rugo[3]; [1]Villejuif, FR, [2]Barcelona, ES, [3]San Francisco, CA/US

13:00 - 14:00	**Type: Industry Satellite Symposium** **Title: Pfizer Oncology - Industry Satellite Symposium: Changing the trajectory of HR+/HER2- mBC: From evidence to clinical practice** Chair(s): Veronique Dieras, FR	**Riga Hall**

13:00 - 13:05 **Welcome and introductions**

13:05 - 13:25 **Treating HR+/HER2- mBC: CDK4/6 inhibitors in current practice and future directions**

13:25 - 13:55 **Transatlantic perspectives: Treating HR+/HER2- mBC in everyday practice: Case presentations with discussion**

13:55 - 14:00 **Meeting close**

14:10 - 14:40	**Type: Keynote lecture** **Title: Keynote lecture: Hereditary breast cancer and PARP inhibitors** Chair(s): Andrew Tutt, GB	**Maritim Hall**
14:10 - 14:10	**Session DOI**	
14:10 - 14:40	**Hereditary breast cancer and PARP inhibitors** M. Robson, New York, US	
14:45 - 16:15	**Type: Multidisciplinary tumour board** **Title: Premenopausal women with early ER+/HER2 negative breast cancer** Chair(s): Pier Franco Conte, IT; Giuseppe Curigliano, IT	**Maritim Hall**
14:45 - 14:45	**Session DOI**	
14:45 - 15:05	**Endocrine therapy in premenopausal women** G. Curigliano, Milan, IT	
15:05 - 15:25	**Estimating the magnitude of clinical benefit in premenopausal ER+/HER2- EBC** P.F. Conte, Padova, IT	
15:25 - 15:45	**Radio-oncology perspective** P. Poortmans, Paris, FR	
15:45 - 16:05	**Surgical perspective in ER + early breast cancer** E. Rutgers, Amsterdam, NL	
16:05 - 16:15	**Q&A**	
16:15 - 16:45	**Type: Coffee break** **Title: Coffee break**	**Exhibition area**

16:45 - 18:15 **Type: Proffered Paper session** **Maritim Hall**
Title: Best abstracts session
Chair(s): Sibylle Loibl, DE; Giuseppe Curigliano, IT

16:45 - 16:45 **Session DOI**

16:45 - 17:00 **108O - Factors predicting relapse in early breast cancer patients with a pathological complete response after neoadjuvant therapy: pooled analysis based on the GBG database**

J. Huober[1], A. Schneeweiss[2], J.-U. Blohmer[3], C. Denkert[4], C. Hanusch[5], C. Jackisch[6], V. Nekljudova[7], F. Seither[7], S. Loibl[7], M. Untch[3]; [1]Ulm, DE, [2]Heidelberg, DE, [3]Berlin, DE, [4]Marburg, DE, [5]München, DE, [6]Offenbach Am Main, DE, [7]Neu-Isenburg, DE

17:00 - 17:15 **86O - Dose-dense adjuvant chemotherapy in early breast cancer: 15 –year results of the phase III Mammella InterGruppo (MIG)-1 study**

E. Blondeaux[1], M. Cantore[2], A. Michelotti[3], B. Conte[1], M. Benasso[4], C. Bighin[1], M. Lambertini[1], F. Poggio[1], L. Del Mastro[1]; [1]Genova, IT, [2]Mantova, IT, [3]Pisa, IT, [4]Savona, SV/IT

17:15 - 17:30 **Invited discussant of 108O and 86O**

P.F. Conte, Padova, IT

17:30 - 17:45 **LBA2 - Everolimus plus aromatase inhibitors vs aromatase inhibitors as maintenance therapy after first-line chemotherapy in HR+/HER2- metastatic breast cancer: final results of the Phase III randomized MAIN-A trial**

V. Guarneri[1], S. Cinieri[2], L. Orlando[2], C. Bengala[3], G. Mariani[4], G. Bisagni[5], A. Frassoldati[6], C. Zamagni[7], G. De Salvo[1], P.F. Conte[1]; [1]Padova, IT, [2]Brindisi, IT, [3]Grosseto, IT, [4]Milano, IT, [5]Reggio Emilia, IT, [6]Ferrara, IT, [7]Bologna, IT

17:45 - 18:00 **149O - Outcome and mutational landscape of patients with PIK3CA-mutated metastatic breast cancer (mBC)**

F. Mosele[1], A. Lusque[2], A. Tran Dien[1], N. Droin[1], C. Le Tourneau[3], L. Lacroix[1], I. Bieche[3], C. Massard[4], F. Bertucci[5], F. André[1]; [1]Villejuif, FR, [2]Toulouse, FR, [3]Paris, FR, [4]Villejuif, CEDEX/FR, [5]Marseille, FR

18:00 - 18:15 **Invited discussant of LBA and 149O**

M. Martín, Madrid, ES

18:30 - 19:30	**Type: Industry Satellite Symposium** **Title: TouchIME - Industry Satellite Symposium: Addressing ongoing clinical challenges: How do we optimize patient outcomes with CDK4/6 inhibition in HR+/HER2- breast cancer?** Chair(s): Stephen Johnston, GB	**Berlin Hall**

18:30 - 18:35 **Introduction and welcome – where are we now?**

S. Johnston, London, GB

18:35 - 18:45 **Challenge 1. How do we optimize patient selection and treatment sequencing for HR+/ HER2- advanced breast cancer therapy in the era of CDK4/6 inhibition? Presentation with panel discus**

N. Harbeck, Munich, DE

18:45 - 18:55 **Challenge 2. How do we optimize AE management with CDK4/6 inhibitors? Presentation with panel discussion. Questions from the audience**

M. Campone, Saint-Herblain, CEDEX/FR

18:55 - 19:10 **Clinical challenges in action. What would you do in our interactive case scenarios? Interactive case studies with audience voting**

S. Johnston, London, GB

19:10 - 19:30 **Moving forward in early breast cancer: Future application of CDK4/6 inhibitors? Presentation with panel discussion. Questions from the audience**

19:30 - 19:30 **Summary from the Chair and meeting close**

S. Johnston, London, GB

18:30 - 19:30 **Type: Industry Satellite Symposium** **Vienna Hall**
Title: Mylan - Industry Satellite Symposium: HER problem is our mission
Chair(s): Javier Cortes Castan, ES; Fatima Cardoso, PT

18:30 - 18:35 **Welcome, introduction, round table and Q&A**
F. Cardoso, Lisbon, PT

18:35 - 18:45 **Prognosis of HER2+ Breast Cancer: How well have we done?**
C. Waller, Freiburg Im Breisgau, DE

18:45 - 19:00 **Future Innovative Treatment Strategies in HER2+ Breast Cancer**
J. Cortes Castan, Barcelona, ES

19:00 - 19:15 **Role of a Biosimilar: Indian Real-World Experience**
N. Rohatgi, New Delhi, Delhi/IN

19:15 - 19:25 **Round table**

19:25 - 19:30 **Conclusions**
F. Cardoso, Lisbon, PT

18:30 - 19:15 **Type: Young Oncologist session** **London Hall**
Title: Vesalius Talk: developing effective leadership skills
Chair(s): Carmen Criscitiello, IT

18:30 - 18:35 **Introduction**
C. Criscitiello, Milan, IT

18:35 - 19:15 **Panel discussion**
M. Martín[1], C. Sotiriou[2]; [1]Madrid, ES, [2]Brussels, BE

04.05.2019

07:45 - 08:30 **Type: Special session** **Riga Hall**
Title: Inflammatory breast cancer
Chair(s): John Martens, NL

07:45 - 07:45 **Session DOI**

07:45 - 07:50 **Introduction**
J. Martens, Rotterdam, NL

07:50 - 08:10 **Clinical characteristics of IBC: Awareness, epidemiology, diagnosis and treatment**
C. Schröder, Groningen, NL

08:10 - 08:30 **What is different in the biology of Inflammatory Breast Cancer?**
S. Van Laere, Antwerp, BE

08:30 - 09:30 **Type: Controversy session** **Vienna Hall**
Title: Multigene testing for treatment decision in early and metastatic breast cancer
Chair(s): Fabrice André, FR

08:30 - 08:30 **Session DOI**

08:30 - 08:40 **Introduction and first vote**

08:40 - 09:00 **Pro**
J. Bergh, Solna, Solna/SE

09:00 - 09:20 **Contra**
V. Guarneri, Padova, IT

09:20 - 09:30 **Second vote and conclusions**

08:45 - 10:15	**Type: Educational session** **Title: Radiation therapy** Chair(s): Philip Poortmans, FR	**Berlin Hall**

08:45 - 08:45 **Session DOI**

08:45 - 09:05 **Current challenges**

R. Orecchia, Milan, IT

09:05 - 09:25 **Individualised target volume selection and dose prescription**

P. Poortmans, Paris, FR

09:25 - 09:45 **Current technical solutions for clinical worries**

M. Algara, Barcelona, ES

09:45 - 10:05 **Can we do even better: Future options**

J.H. Maduro, Groningen, NL

10:05 - 10:15 **Q&A**

08:45 - 10:15	**Type: Educational session** **Title: Metastatic breast cancer: HER2-/HR positive** Chair(s): Nicholas Turner, GB; Fatima Cardoso, PT	**Maritim Hall**

08:45 - 08:45 **Session DOI**

08:45 - 09:05 **Advances in targeting the estrogen receptor**
S. Johnston, London, GB

09:05 - 09:25 **Resistance to CDK4/6 inhibitors: Clinical implications**
N. Turner, London, GB

09:25 - 09:45 **Sequencing of targeted therapies for the individual patient**
F. Cardoso, Lisbon, PT

09:45 - 10:05 **When chemotherapy is required**
N. Harbeck, Munich, DE

10:05 - 10:15 **Q&A**

08:45 - 10:15 **Type: Special session** **Riga Hall**
Title: In collaboration with Europa Donna
Chair(s): Mona Knotek-Roggenbauer, AT; Karen Benn, IT; Tanja Spanic, SI

08:45 - 08:45 **Session DOI**

08:45 - 08:45 **Part I: ECIBC- European Commission Initiative on Breast Cancer Implementation**

08:45 - 09:00 **Overview of ECIBC**
A. Janusch-Roi, Ispra, IT

09:00 - 09:20 **QASDG (Quality Assurance Scheme Development Group) and the pilot program**
R. Mansel, Cardiff, GB

09:20 - 09:30 **Discussion and Conclusions**

09:30 - 09:30 **Part II: Advocacy for special groups: What is needed**

09:30 - 09:50 **Advocacy to ensure access and support for young women**
T. Spanic, Ljubljana, SI

09:50 - 10:10 **Advocacy to ensure access and support for women with MBC**
M. Knotek-Roggenbauer, Vienna, AT

10:10 - 10:15 **Discussion and Conclusions**

09:45 - 10:15 **Type: Spotlight** **Vienna Hall**
Title: Spotlight on breast cancer survivorship
Chair(s): Shani Paluch-Shimon, IL

09:45 - 09:45 **Session DOI**

09:45 - 10:05 **Spotlight on breast cancer survivorship**
I. Vaz-Luis, Villejuif, FR

10:05 - 10:15 **Discussion**

10:15 - 10:45 **Type: Coffee break** **Exhibition area**
Title: Coffee break

10:45 - 12:45 **Type: Mini oral session** **Berlin Hall**
Title: Mini oral session 2
Chair(s): Jean-Yves Pierga, FR; Michael Untch, DE

10:45 - 10:45 **Session DOI**

10:45 - 10:50 **5O - TILs in ER+/HER2- breast cancer**
C. Criscitiello[1], A. Vingiani[2], P. Maisonneuve[2], G. Viale[1], G. Viale[1], G. Curigliano[1]; [1]Milan, IT, [2]Milano, IT

10:50 - 10:55 **Q&A**

10:55 - 11:00 **LBA1 - miRNA expression profiles in BRCA1-associated breast cancers reveal upregulation of specific miRNAs in tumors lacking a clear second hit in a large proportion of the tumor**
M. Van Heetvelde[1], M. Van Bockstal[2], J. Van Dorpe[3], K. De Leeneer[1], A. Vral[1], K. Claes[3]; [1]Ghent, BE, [2]Woluwe-Saint-lambert, BE, [3]Gent, BE

11:00 - 11:05 **Q&A**

11:05 - 11:10 **87O - Impact of older age on the locoregional and distant breast cancer recurrence risk, A large population-based study.**
A. de Boer[1], H. van der Hulst[1], W. van der Plas-Krijgsman[1], N. De Glas[1], P. Marang-van de Mheen[1], S. Siesling[2], G.-J. Liefers[1], E. Bastiaannet[1], J. Portielje[1]; [1]Leiden, NL, [2]Utrecht, NL

11:10 - 11:15 **Q&A**

11:15 - 11:20 **88O - Validation of the American Joint Committee on Cancer new prognostic stage groups for HER2-positive breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the prospective ShortHER trial.**

M.V. Dieci[1], G. Bisagni[2], A. Brandes[3], A. Frassoldati[4], M. Donadio[5], O. Garrone[6], F. Piacentini[7], S. Balduzzi[7], V. Guarneri[1], P.F. Conte[1]; [1]Padova, IT, [2]Reggio Emilia, IT, [3]Bologna, IT, [4]Ferrara, IT, [5]Torino, IT, [6]Cuneo, IT, [7]Modena, IT

11:20 - 11:25 **Q&A**

11:25 - 11:30 **89O - Impact of delayed adjuvant chemotherapy: The Royal Marsden Hospital (RMH) Experience**

A. Okines, E. Kipps, T. Irfan, M. Coakley, V. Aggelis, B. Asare, S. Johnston, M. Parton, N. Turner, I. Smith; London, GB

11:30 - 11:35 **Q&A**

11:35 - 11:40 **90O - The role of dose-dense (DD) adjuvant chemotherapy (CT) in HER2-positive (HER2+) early breast cancer (BC) patients (pts) before and after the introduction of trastuzumab (T): exploratory analysis of the GIM2 trial**

M. Lambertini[1], M. Bruzzone[1], F. Poggio[1], B. Conte[1], E. de Azambuja[2], G. Bisagni[3], M. De Laurentiis[4], S. de Placido[4], F. Cognetti[5], L. Del Mastro[1]; [1]Genova, IT, [2]Brussels, BE, [3]Reggio Emilia, IT, [4]Napoli, IT, [5]Rome, IT

11:40 - 11:45 **Q&A**

11:45 - 11:50 **91O - Circulating tumor DNA and disease recurrence in early stage breast cancer: from a case-control study to a prospective longitudinal trial**

S. Di Cosimo[1], V. Appierto[1], E. Ortolan[1], F. Dell'Angelo[1], M. Silvestri[1], G. Bianchi[2], S. Folli[2], L. De Cecco[1], G. Pruneri[2], M.G. Daidone[1]; [1]Milan, IT, [2]Milano, IT

11:50 - 11:55 **Q&A**

11:55 - 12:00 **92O - Validating the CTS5 algorithm with the IDEAL study cohort.**

I. Noordhoek[1], E. Blok[1], E. Meershoek-Klein Kranenbarg[1], H. Putter[1], M. Duijm-De Carpentier[1], C. van de Velde[2], G.-J. Liefers[1], J. Kroep[1], J. Portielje[1]; [1]Leiden, NL, [2]Amsterdam, NL

12:00 - 12:05 **Q&A**

12:05 - 12:10 **93O - Impact of tamoxifen (TAM) serum concentration on side effects among premenopausal patients (pts) with early breast cancer (BC) in the prospective multicenter CANTO cohort.**

A. Ferreira[1], A. Paci[2], A. Di Meglio[3], F. André[3], S. Everhard[4], A.-L. Martin[4], L. Fasse[3], G. Menvielle[4], I. Vaz-Luis[3], B. Pistilli[3]; [1]Lisbon, PT, [2]Villejuif Cedex, FR, [3]Villejuif, FR, [4]Paris, FR

12:10 - 12:15 **Q&A**

12:15 - 12:20 **199O - Long-term cardiac outcomes of HER2+ breast cancer patients treated in the ALTTO trial**

D. Eiger[1], N. Ponde[2], D. Agbor-Tarh[3], L. Korde[4], A. Moreno Aspitia[5], R. Rodeheffer[6], M. Ewer[7], T. Suter[8], M. Piccart[2], E. de Azambuja[2]; [1]Brussels, São Paulo/BE, [2]Brussels, BE, [3]Kingussie, GB, [4]Bethesda, US, [5]Jacksonville, US, [6]Rochester, US, [7]Houston, TX/US, [8]Bern, CH

12:20 - 12:25 **Q&A**

12:25 - 12:30 **8O - The mutational profile of IBC reveals higher mutational burden, deficiency of homologous recombination and NOTCH signalling**

S. Van Laere[1], P. Finetti[2], C. Rypens[1], D. Birnbaum[2], P. Vermeulen[3], P. Viens[4], L. Dirix[3], F. Bertucci[2]; [1]Antwerp, BE, [2]Marseille, FR, [3]Wilrijk, BE, [4]Marseille, CEDEX 9/FR

12:30 - 12:35 **Q&A**

12:35 - 12:40 **9O - Para-necrotic expression of VEGFA metagene signature identified by single-cell profiling**

T. Karn[1], C. Denkert[2], K. Weber[3], P. Jank[4], A. El-Balat[1], A. Rody[5], M. Untch[4], S. Loibl[3], L. Pusztai[6], U. Holtrich[1]; [1]Frankfurt Am Main, DE, [2]Marburg, DE, [3]Neu-Isenburg, DE, [4]Berlin, DE, [5]Lübeck, Schleswig-Holstein/DE, [6]Houston, TX/US

12:40 - 12:45 **Q&A**

10:45 - 12:15	**Type: Educational session** **Title: Metastatic breast cancer: TNBC** Chair(s): Alexandru Eniu, RO; Veronique Dieras, FR	**Maritim Hall**

10:45 - 10:45 **Session DOI**

10:45 - 11:05 **Understanding the biology of TNBC: Where are we in 2019?**
J. Reis-Filho, New York, NY/US

11:05 - 11:25 **Harnessing the immune response in TNBC: Are we mastering it?**
P. Schmid, London, GB

11:25 - 11:45 **Who does NOT need PARP inhibition?**
G. Curigliano, Milan, IT

11:45 - 12:05 **Is chemotherapy becoming obsolete in TNBC?**
A. Eniu, Cluj-Napoca, RO

12:05 - 12:15 **Q&A**

10:45 - 12:15	**Type: Educational session** **Title: Innovative treatment across subtypes** Chair(s): Lajos Pusztai, US; Nadia Harbeck, DE	**Vienna Hall**

10:45 - 10:45 **Session DOI**

10:45 - 11:05 **Changing paradigms in sequencing of treatment modalities in early stage breast cancer**

N. Harbeck, Munich, DE

11:05 - 11:25 **The role of metastatic tumor profiling and targeted therapies**

L. Pusztai, Houston, TX/US

11:25 - 11:45 **Emerging role of antibody-drug conjugates**

H. Rugo, San Francisco, CA/US

11:45 - 12:05 **Immune therapy as a generalistic approach**

C. Criscitiello, Milan, IT

12:05 - 12:15 **Q&A**

10:45 - 12:15 **Type: Special session** **Riga Hall**
Title: The changing paradigm for breast cancer surgery
Chair(s): Tibor Kovacs, GB; Fatima Cardoso, PT

10:45 - 10:45 **Session DOI**

10:45 - 10:50 **Introduction**
T. Kovacs, London, GB

10:50 - 11:10 **Observation of DCIS**
E. Rutgers, Amsterdam, NL

11:10 - 11:30 **Sentinel lymph node biopsy after neoadjuvant therapy: Where do we go from there?**
I. Rubio, Barcelona, ES

11:30 - 11:50 **Oncoplastic breast conservative surgery for multicentric tumors: No more exclusion criteria for clinical trials**
T. Kovacs, London, GB

11:50 - 12:10 **Do all BRCA carriers with breast cancer benefit from bilateral mastectomy?**
R. Ponzone, Candiolo, IT

12:10 - 12:15 **Conclusions**
F. Cardoso, Lisbon, PT